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ABSTRACT 
 
GENETIC AND EPIGENETIC EFFECT OF ESTROGEN ON 
MESENCHYMAL STEM CELL MAINTENANCE AND 
DIFFERENTIATION 
 
 
Ceylan Verda Bitirim 
Ph.D. in Molecular Biology and Genetics 
Supervisor: Assoc. Prof. Dr. Işık Yuluğ 
October 2013, Pages 151 
 
 
Mesenchymal stem cells (MSCs) have the potential to differentiate into 
multiple cell types and immune privileged characteristics. These features make 
MSCs a hope in tissue engineering and cell based treatment applications.  
Tremendous amount of studies were carried out in order to produce an ideal 
biomaterial as a scaffold for cell transplantation. In recent studies, carbon 
nanotubes (CNT) were identified as a novel scaffold array due to their unique 
physical, chemical and electrical properties among the other biomaterials.The 
effect of estrogen hormone on the regulation of MSC maintenance, proliferation 
and differentiation was reported. However, its role in maintenance of MSCs on 
scaffold materials such as CNTs and the genetic and epigenetic regulation of 
MSC differentiation have not fully been elucidated.  Therefore our aim was to 
examine the possible role of estrogen in the MSCs’ maintenance seeded on 
CNT surfaces and genetic and epigenetic regulation of the key transcription 
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factors involved in adipogenic, osteogenic and chondrogenic differentiaton of 
MSCs. Our results revealed the enhanced effect of estrogen on the viability of 
MCSs which were seeded and incubated on multiwalled carbon nanotubes 
(MWCNT). In addition we demonstrated that passaging causes decrease of cell 
viability and the number of attached cells on CNT materials. We have also 
shown the effect of estrogen on the epigenetic and genetic regulation of MSC 
differentiation. Estrogen treatment decreased the expression of major 
adipogenic transcription factors; C/EBPα, FABP4, PPARγ, Adipsin and 
increased key osteogenic transcription factor RUNX2 in MSCs from both 
normal female and ovariectomized rats, suggesting inhibitory and stimulatory 
effect of estrogen on adipogenesis and osteogenesis respectively. We have also 
shown that the subcellular localization of PPARγ and ETS1 is changed in 
response to estrogen deficiency. Among modified histones, we found that 
H3K27me2, H3K27me3 and H3K36me2 protein levels were reduced after 
estrogen treatment both in female and ovariectomized animals. In addition, 
ChIP analysis showed that estrogen treatment caused an increase in 
H3K27me2, H3K27me3 and ERα levels at the promoters of C/EBPα, FABP4, 
PPARγ, Adipsin and RUNX2.  Bisulfite sequencing analysis revealed that in 
the absence of estrogen, DNA hypermethylation was established in C/EBPα and 
PPARγ promoters whereas in ERα promoters CpG hypomethylation was 
observed after estrogen treatment. In conclusion, estrogen causes epigenetic and 
genetic changes in maintenace and differentiation of MSCs. Understanding the 
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effect of estrogen on the genetic and epigenetic regulation of the major 
transcription factors may lead to clues for new treatment in chronic diseases 
such as obesity, osteoporosis and ostearthiritis.  
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ÖZET 
 
ÖSTROJEN HORMONUNUN MEZENKİMAL KÖK 
HÜCRELERİN MUHAFAZASINDAKİ VE 
FARKLILAŞMASINDAKİ GENETİK VE EPİGENETİK 
ETKİSİ 
 
 
Ceylan Verda Bitirim 
Moleküler Biyoloji ve Genetik Doktorası 
Tez Yöneticisi: Doç. Dr. Işık Yuluğ 
Ekim 2013, Sayfa 151 
 
 
Mezenkimal kök hücreler (MKH) kemik, yağ, kıkırdak, sinir ve karaciğer 
hücrelerine dönüşebilme potansiyeli olan, immün reaksiyon oluşturma özelliği 
olmayan hücrelerdir. Bu özellikler kök hücreleri doku mühendisliği ve hücre 
tedavisi alanları için yeni bir umut haline getirdi. Hücre transplantasyonunda 
kullanılmak üzere ideal yüzey üretmek için pek çok çalışma yürütüldü. Son 
yıllarda farklı fiziksel, kimyasal ve elektriksel özelliklerinden dolayı karbon 
nanotüpler (KNT) yeni biyomateryal yüzeyler olarak tanımlandı. Östrojen 
hormonunun mezenkimal kök hücre devamlılığı, çoğalması ve farklılaşması 
üzerine etkileri rapor edilmiştir. Fakat östrojenin biyomateryal yüzey üzerindeki 
mezenkimal kök hücrenin devamlılıgındaki ve mezenkimal kök hücre 
farklılaşmasındaki genetik ve epigenetik rolü tam olarak araştırılmamıştır. Bu 
nedenle, bu çalışmada östrojenin karbon nantüp üzerine ekilen kök hücrelerin 
devamlılığındaki ve adipojenik, östeojenik ve kondrojek farklılaşmaya katılan 
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anahtar transkripsiyon faktörlerinin genetik ve epigenetik regülasyonundaki 
rolünü araştrmak amaçlanmıştır. Sonuçlarımız östrojenin çok duvarlı karbon 
nanotüpler üzerindeki MKHlerin canlılıgını arttırıcı etkisini göstermiştir. Ayrıca 
hücre canlılıgı ve KNT materyalin üzerine yapışan MKH sayısının passajlama 
ile azaldıgını gösterdik. Bu çalışmada östrojenin MKH farklılaşmasının genetik 
ve epigenetik regülasyonuna etkisini gösterebildik. Östrojen tedavisi, normal 
dişi ve overi alınmış dişiden alınan MKH’de temel adipojenik transkripsiyon 
faktörler olan C/EBPα, FABP4, PPARγ, Adipsinin gen ifadesini azaltırken, 
anahtar transkripsiyon faktörü olan RUNX2 nin ifadesini arttırır. Bu sonucun 
östrojenin adipojenik farklılaşma üzerine baskılayıcı etkisini, östeojenik 
farklılaşma üzerine arttırıcı etkisini gösterdiği söylenebilir. PPARγ ve diğer 
transkripsiyon faktörü ETS1 proteinlerinin hücresel lokalizasyonunun östrojen 
yokluguna bağlı değişimi ayrıca gösterilmiştir. Diğer modifiye histonlar 
arasında, H3K27me2, H3K27me3 ve H3K36me2 protein düzeylerinin östrojen 
tedavisinden sonra azaldığını bulduk. Ek olarak, kromatin immünopresipitasyon 
analizleri H3K27me2, H3K27me3 ve ERα düzeylerinin C/EBPα, FABP4, 
PPARγ, Adipsin ve RUNX2 promotörleri üzerinde östrojen tedavisi sonucu 
arttıgını gösterdi. Bisülfit sekanslama analizleri östrojen yoklugunda C/EBPα 
ve PPARγ promotörleri üzerinde DNA hipermetilasyonu görülürken, ERα 
promotöründe CpG hipometilsayonu görüldü. Sonuç olarak, östrojen MKH 
devamlılıgı ve farklılaşmasında epigenetik ve genetik değişimlere yol açar. 
Östrojenin temel transkripsiyon faktölerinin regülasyonundaki etkisinin 
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anlaşılması obezite, osteoporoz ve osteoartirit gibi kronik hastalıkların tedavisi 
için yeni ipuçları yaratır.  
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CHAPTER 1 
INTRODUCTION 
 
In the last several decades researchers have been trying to understand and 
explain complex processes involved in cellular development and molecular 
factors which regulate cell differentiation and formation of multi-cellular 
organisms. However several questions remained unresolved until 1998. 
Isolation of human pluripotent stem cells in 1998 has provided new 
opportunities to answer the questions about human development and 
fundamentals of life. 
 
Stem cells are unspecialized cells that have self-renewal ability and can 
differentiate into specialized cells of the body (http://stemcells.nih.gov). They 
can be categorized according to their timing or potency. According to their 
potency abilities and origin, different types of stem cells were shown in Figure 
1.1. 
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Figure 1.1 Type of stem cells and their origin; pluripotent embryonic stem cells 
(ES), induced pluripotent stem cells (iPS), and multipotent fetal and adult stem 
cells (Figure is adopted from 
1
)   
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Based on their potency, stem cells can be classified as totipotent, pluripotent, 
multipotent and unipotent. Totipotent stem cells differentiate into the cells of 
three embryonic germ layers; ectoderm, endoderm, mesoderm and extra 
embryonic tissues, whereas pluripotent stem cells differentiate into the cells of 
three embryonic germ layers, but cannot give rise to the cells of the extra 
embryonic tissue. Multipotent stem cells can differentiate into the cell types 
from other different tissues that they originated. Unipotent stem cells can give 
rise only one specific cell lineage (http://stemcells.nih.gov). Zygote or fertilized 
egg is a single totipotent cell and generates all the cells in the body, whereas 
embryonic stem cells (ESC) are pluripotent cells and derived from the inner cell 
mass of an early mammalian embryo
2,3
. Adult stem cells, are usually 
multipotent and reside in several specific organs of adults
4,5
. 
 
ESCs are undoubtfully key source to understand molecular basis of cellular 
development as well as cellular threapeutic applications. However due to 
ethical reasons regarding to the use of human embryo, the scientists focused on 
the usage of induced pluripotent stem cells (iPSC) and adult stem cells (ASC). 
iPSCs were first isolated by transfecting four key transcription factors; Oct 4, c-
MYC, Sox 2, Klf 4 into mouse fibroblast to differentiate them into embryonic- 
like stem cells in 2006
6
. This invention seemed to overcome the ethical 
obstacles against the using of embryo. However the methods of induction with 
retro viral vectors and their ability to form teratomas are still some of the 
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factors which may limit their usage.  
 
Among ASCs, mesenchymal stem cells (MSC), also referred to as bone marrow 
derived stromal cells, have became a potential cell source for regenerative 
medicine, stem cell-based therapy and tissue engineering applications due to 
their unique features like differentiation potential, nonimmunogenic 
characteristics and homing ability
7,8
.  
 
In this study, we aimed to investigate the role of estrogen in the maintenance 
and differentiation of MSCs. In addition to normal culture conditions, we also 
examined estrogen’s effect on MSCs when cultured on carbon nanotube arrays 
(CNTs). We further investigated the genetic and epigenetic changes during the 
differentiation of MSCs by estrogen hormone since our previous studies 
showed that estrogen enhances proliferation and inhibits apoptosis of MSCs.  
 
In the introduction section first I will briefly explain stem cells, ESCs, iPS cells, 
ASCs. Then the importance of MSCs in tissue engineering applications will be 
defined. The functions and regulation mechanisms of estrogen hormone and the 
basic concepts of epigenetics will be explained afterwards. Finally, the 
introduction chapter will end with the explanation of the epigenetic and genetic 
regulation of MSCs differentiation upon estrogen treatment. 
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1.1 EMBRYONIC STEM CELLS AND INDUCED 
PLURIPOTENT STEM CELLS 
 
Fertilized oocyte undergoes very rapid cellular proliferation which is defined as 
cleavage stage of early development. ES cells are formed in the inner cell mass 
(ICM) at this stage. Following cleavage hollow of cells are distributed to the 
appropriate parts of the developing embryo and this process is called 
gastrulation. Formation of three germ layers, endoderm, ectoderm and 
mesoderm, is the final products of gastrulation.  
 
ESCs were first isolated by Evans and Kaufman in 1981 from ICM of mouse 
embryo and from human embryo by Thomson in 1998
2
. They have indefinite 
self-renewal capacity and broad differentiation potential to develop cells 
representative of three germ layers
9
.  
 
When they were injected into mouse blastocysts, they fulfill all developmental 
requirements differentiating into the cells of three embryonic germ layers and 
transmitting to the germline of chimeric animals
9
. In addition, teratoma and 
embryoid body formations are evidences of pluripotency properties of these 
cells in vivo and in vitro respectively
10
. Maintenance of pluripotency capability 
of ESCs is provided by expression of key pluripotency genes; Oct4, Sox2, and 
Nanog
11,12
.  
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Two X chromosomes cytologically or functionally are active in undifferentiated 
ESCs
13
. During cell cycle, ESCs undergo symmetric division and generates two 
daughter cells both of which maintain their stem cell identity. The cell cycle 
structure of ESCs can be characterized by short G1 phase which can account for 
the rapid rate of cell division
14
 . Gı phase activate the cylin dependent kinases 
(Cdk) in order to begin new round of replication. When ES cells undergo the 
differentiation, cell cycle structure changes in order to extend significantly G1 
phase
15
. 
 
Both human and mouse ESCs require a feeder layer from irradiated mouse 
fibroblasts. It was well established that leukemia inhibitory factor (LIF) is an 
important mediator which keeps mouse ESCs in undifferentiate state through 
activation of JAK/Stat3 signaling pathway
16,17
.  When LIF is added into the cell 
culture medium, mouse ESCs can also grow in the absence of feeder layer
17,18
. 
On the contrary, LIF addition does not support undifferentiated proliferation of 
human ES cells without feeder layer. On the other hand, self renewal capacity 
of human ESCs is controlled by different factors like Fgf2, TGF-β, noggin, 
activin, and Wnt
18,19
.  
 
Thanks to their ability to self-renewal and differentiaton potential into the cell 
types from all germ layers, ESCs have been considered as a promising source 
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for cell-based therapy in treatment of several degenerative diseases such as 
diabetes mellitus, Parkinson’s disease, Alzheimer, spinal cord injury20 and 
osteogenesis imperfecta
21,22
.  
 
Despite the advantages of ESCs as a promising tool for cell based therapies, 
there are also some medical and ethical pitfalls
23
. Since their isolation from 
blastocyst requires the destruction of the embryo, different political and 
religious groups are opposed to ESC research. In addition, ESCs cause immune 
reactions in the host and as mentioned above have ability to form teratomas
22
.  
Therfore, due to these concerns,   researchers sought alternative pluripotent 
stem cell sources. The reprogramming of fibroblasts to ESC-like cells, which 
was accomplished by Takahashi and Yamanaka in 2006, was a new hope for 
stem cell researches
6
. The invention of induced pluripotent stem cells is 
considered as another major breakthrough in stem cell research field.  
 
Induced pluripotent cells were directly generated from mouse embryonic or 
adult fibroblast cells by introducing combining of four selected factors; Oct3/4, 
Sox 2, Klf 4, c-Myc. These transcription factors play key roles in the induction 
of pluripotency of somatic cells. The factors were chosen among 24 candidate 
genes. These critical four genes, which are called as Yamanaka factors, were 
introduced to fibroblasts by retroviral transfection
6, 24
.  
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The iPS cells and ESCs share lots of similarities in many respects. First of all, 
iPS cells can give rise to cells from three embryonic germ layers; ectoderm, 
endoderm and mesoderm as exactly similar to ESCs. Moreover, the 
pluripotency ability of iPS cells was demonstrated by teratoma formation after 
the subcutaneous injection into nude mice and embryoid body formation in 
vitro like ESCs. Also the cells are expressing ES cell markers like Nanog, Sox2, 
Eras, Cripto and Dax1. Furthermore, analyses of genome-wide expression 
patterns and global histone modifications have shown a high degree of 
similarity between ESCs and iPSCs. Finally, iPSC clones exhibit similar 
morphology to ES cells such as round shape, large nucleoli and scant 
cytoplasm
25,26
. 
 
In light of these considerations, iPSCs are seems to be promising tools for cell 
based therapy, regenerative medicine and drug development overcoming the 
difficulties regarding the use of human embryos and tissue rejection problem 
following transplantation in patients. iPSCs enable patient-specific iPS cell 
based therapy and minimize rejection. In a previous study, it was reported that 
generation of iPS cells from patients with different genetic diseases including 
Parkinson disease, adenosine deaminase deficiency-related severe combined 
immunodeficiency, Huntington disease, Down syndrome and juvenile-onset 
diabetes mellitus offers opportunity to investigate the causes of these diseases 
and drug development
27
. Alternatively, if the mutation which causes a disease 
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was known, it could be repaired in iPS cells by gene targeting. Afterwards, the 
healthy tissue-specific cells can be transplanted into the patients following 
differentiation
24,28
. Generation and threapeutic applications of iPS cells was 
shown in Figure 1.2. 
 
 
 
Figure 1.2 Generation and applications of iPS cells (Figure is adopted from
28
) 
 
On the other hand, a major limitation of this technology is the use of viruses 
that integrate into the genome. Using viruses is also associated with the risk of 
tumor formation due to reactivation of the viral trans-genes. Thereby, after 
invention of the iPSCs in 2006, transient transfection methods were extensively 
studied. To improve the efficiency and to overcome the viral transfection issue, 
different cell sources such as human dermal fibroblasts, foreskin fibroblasts, 
fetal liver cells and hepatocytes have been used with different delivery 
techniques such as inducible lentiviral vectors
29
, adenovectors
35
, plasmids
26
 
Cre/LoxP system after single plasmid transfection
36
. PiggyBac transposons
31,32
, 
chemical compounds
33
, purified recombinant proteins without using any virus 
or plasmid
40 
and synthetic modified mRNA molecules which encode the 
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Yamanaka Factors and Lin28
41 
for reprogramming. However, the efficiency of 
all these approaches is extremely low. Furthermore, the epigenetic memory 
problem of iPS cells has not been already solved. Although, somatic cells were 
reprogrammed to pluripotent cells resembling ESCs, these generated iPS cells 
keep the epigenetic memory of their tissue of origin 
34
. 
 
1.2 ADULT STEM CELLS 
 
Adult stem cells (ASC) are undifferentiated cells which reside in a specific 
organ or tissue. The major role of ASCs is to maintain the homeostasis and to 
repair the tissue in which they are found. Most types of adult stem cells are 
multipotent. They have long term, but not unlimited, self-renewal ability and 
give rise to mature specialized cells
35
. Typically, adult stem cells divide to 
generate an intermediate cell; progenitor or precursor cell. Progenitor cells 
develop into terminally differentiated cells
36,37
.  
 
ASCs can remain quiescent for a long time in tissue. The specific area in which 
stem cells reside is called as “niche” (http://stemcells.nih.gov). The ASC 
reservoir in tissues or organs is protected by asymmetric cell division. 
Asymmetric cell division is regulated by a niche-derived signals
38
. After the 
cell division, one of the two daughter cell contacts the niche retaining their stem 
cell identity, whereas the other daughter cell leaves the niche and committed to 
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differentiate
38
. Under normal conditions, in case of the tissue injury or when 
then the maintenance of the tissue is required ASCs are triggered in order to 
divide and recruit
41
. ASCs show clonal growth. Thanks to the asymmetric cell 
division, the clones contain many cells that have proliferation potential of 
progenitor cell
37
. Until now, the existence of ASCs was identified in many 
tissues and organs and such as blood, bone marrow, liver, skin, testis, ovarian 
epithelium, muscle, adipose tissue, heart, teeth and brain. Different types of 
adult stem cells and their location in the body in human was listed in Table 1.1. 
 
Adult bone marrow and peripheral blood contain hematopoietic stem cells 
(HSC) and MSCs. The first identified ASCs population was HSCs. These cells 
were first mentioned by Till and McCulloch in 1961
49
. HSCs give rise to all 
lymphocyte and blood cell types
41,42
. 
 
1.2.1 MESENCHYMAL STEM CELLS 
 
MSCs were first identified in stormal part of bone marrow in 1966 by 
Friedenstein
43
 and further characterization was accomplished by Pittenger in 
1999
44
. It was demonstrated that human MCSs can give rise to several different 
cell types including osteocytes, myoctes, adipocytes
45,46
, chondrocytes
47
, 
cardiomyocytes
48
 and neurons
49
. The types of cells that are derived form MSC 
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Cell Type Tissue-Specific 
Location 
Cells or Tissues 
Produced 
Hematopoietic stem 
cells 
Bone marrow, 
peripheral blood 
Bone marrow and blood 
lymphoid hematopoietic 
cells 
Mesenchymal stem 
cells 
Bone marrow, 
peripheral blood 
Bone, cartilage, tendon, 
adipose tissue, muscle, 
marrow stroma, neural cells 
Neural stem cells Ependymal cells, 
astrocytes, subventricular 
zone of the central 
nervous system 
Neurons, astrocytes, 
oligodendrocytes 
Hepatic stem cells In or near the terminal 
bile ductules (canals of  
Hering) 
Oval cells that 
subsequently generate 
hepatocytes and ductular 
cells 
Pancreatic stem cells Intraislet, nestin-
positive cells, oval cells, 
duct cells 
Beta cells 
Skeletal-muscle stem 
cells or satellite cells 
Muscle fibers Skeletal muscle fibers 
Stem cells of the skin 
(keratinocytes) 
Basal layer of the 
epidermis, bulge zone of 
the hair follicles 
Epidermis, hair follicles 
Epithelial stem cells 
of the lung 
Tracheal basal and 
mucussecreting cells, 
bronchiolar Clara cells, 
alveolar type II 
pneumocyte 
Mucous and ciliated cells, 
type I and II pneumocytes 
Stem cells of the 
intestinal epithelium 
Epithelial cells located 
around the base of each 
crypt 
Paneth’s cells, brush-
border enterocytes, 
mucussecreting goblet cells, 
enteroendocrine cells of the 
villi 
 
Table 1.1  Different types of adult stem cells and their location in the body 
(Reproduced with permission from Körbling, M et al.41, Copyright 
Massachusetts Medical Society) 
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was shown in Figure 1.3. In addition, MSCs support the long-term 
hematopoiesis and expansion of embryonic stem cells via expressing cytokines 
and growth factors
48
. MSCs have been isolated from different tissues other than 
bone marrow, such as adipose tissue, amniotic fluids, periosteum, fetal tissues, 
dental pulp, peripheral blood, liver and spleen. Morphologically MSCs show 
heterogeneity, ranging from narrow spindle shaped to cuboidal, packed cells 
51,52 . 
 
Phenotypically, adult human MSCs are positive for a number of markers, such 
as CD90 (Thy-1), CD117 (c-kit), CD71, CD105, CD73, CD44, and adhesion 
molecules like VCAM-1 (vascular cell adhesion molecule), ICAM-1 
(intercellular adhesion molecule), CD166 (activated leukocyte cell adhesion 
molecule) and CD29 (integrin beta-1). They do not express hematopoietic 
markers; CD34, CD45, CD14, co-stimulatory molecules CD40, CD86, CD80 
48,51,52,53
. 
      
 
Adult human MSCs express major histocompatibility complex (MHC) class I, 
whereas human leukocyte antigen (HLA) class II antigens and MHC class II 
expressions are absent. In addition MSCs have an immunosuppressive function. 
They inhibit T cell and B cell proliferation and differentiation of B cells into 
plasma cells.  This phenotype shows the non-immunogenic character of the
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Figure 1.3 Types of cells differentiated from bone marrow derived MSC and 
their germ layers (Figure is adopted from 
54
) 
 
MSC
51
,
55
. It has been shown by in vivo models that  MSCs can prevent and treat 
graft-versus-host disease (GVHD) seen in allogeneic stem cell transplantation
50
.  
Also MSCs may be used in the treatment of autoimmune disorders
55-57
.   
 
While MSCs are differentiating into different cell lineages under appropriate 
conditions, expression of pluripotency genes such as Oct4, Sox2, TERT 
(telomerase reverse transcriptase) decrease. The expression of transcription 
factors, which are involved in MSC differentiation such as RUNX2, ALP, 
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PPARγ, C/EBPα, are also regulated by epigenetic mechanisms. Histone 
modifications and CpG methylayion states on these genes are changed upon 
differentiation induction. Thus, the presence of these epigenetic regulation 
mechanisms is crucial for MSC differentiation
58,59.
 
 
MSCs may follow different ways during repair of an injured tissue or organ. 
First, host MSCs can enter into peripheral blood circulation and migrate to 
target the ischemic tissue. Secondly, MSCs that were injected exogenously can 
enter the blood circulation and home to injured tissue or inflammation site. As 
third mechanism, MSCs can be locally injected at the site of injury. The 
injected MSCs may differentiate into tissue specific stem cells to regenerate. On 
the other hand, the methods using in MSC homing/trafficking are still 
inadequate to determine the exact location
7,52,60
 . 
 
Due to their differentiation potential and immune-privileged characteristic, 
MSCs derived from bone marrow is considered as promising cell source for 
tissue engineering applications in recent years
61
. However, the adhesion of stem 
cells on ECM is the major concern for particular growth and differentiation. 
Different types of synthetic and natural biomaterials were demonstrated as 
scaffold material for MSC transplantation especially for therapeutic 
applications of cartilage and bone defects
61-63
. Porous ceramics cylinders and 
biodegradable polymers; poly-L-lactide (PLA) and poly-Llactide-co-glycolide 
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(PLGA), hydrogel alginate and collagen type gels were demonstrated as 
alternative scaffolds
60-66
. Adhesion, proliferation and differentiaton of bone 
marrow derived MSCs on these constructs were demonstrated through in vivo 
and in vitro experiments
60,64,66,67
. For instance, repairing of full-thickness 
articular cartilage defects in knees of rabbits and bone defects in dogs 
successfully accomplished through the autologous-MSC transplantation on 
collagen-type-1 gel and porous ceramics cylinders respectively
66,69
.  
 
1.3 USE OF CARBON NANOTUBES AS THREE- 
DIMENSIONAL SCAFFOLD MATERIAL 
 
The fundamental principle of tissue engineering approach is to repair and 
restore the diseased and damaged tissue with different strategies
70
. Over the 
past decades, using of biodegradable and biocompatible scaffolds in tissue 
engineering field have developed.  
 
The major purpose is producing a construct, which can structurally and 
functionally mimic the extra cellular matrix (ECM) of cells
67,71
 , to transplant 
into diseased or defective tissue after seeding the autologous cells onto these 
scaffolds. That’s why, producing an ideal scaffold protein, which can support 
different cell types and capable of stimulating cell growth, adhesion and 
proliferation mimicking the native tissue, is a critical point in tissue 
17 
 
engineering.  
 
In last decade, tremendous amount of attempt have been applied to produce 
better scaffold construct which can closely mimic the ECM of native 
tissues
67,72
. For this purpose different kinds of biomaterials were used as 
scaffold such as porous ceramics cylinders, biodegradable polymers like poly-
L-lactide (PLA) and poly-L-lactide-co-glycolide (PLGA), hydrogel alginate and 
collagen type gels
60-66
. In addition, the importance of topographical pattern on 
cell viability was also demonstrated in a number of studies. Especially it was 
shown that dimension and roughness features of surface induce cell growth and 
support attachment of the cells
72
. Thereby, scaffold proteins are promising tools 
in tissue engineering due to their patterned surface and nanometer scale 
dimension
73,74
. It was reported that the rougher surface induced gene expression 
of fibroblast cells
67
. Moreover, surface properties of scaffolds have potential to 
develope new environment which is able to stimulate cell proliferation and 
adhesion
72
. Due to their patterned surface and nanometer scale dimension, 
scaffold proteins are considered as promising tools in tissue engineering
73-75
.  
 
In recent years, carbon nanotubes (CNTs) have became an attractive alternative 
scaffold material in tissue regeneration field due to their dimension, chemical 
stability, their high tensile mechanical strength, electrical conductivites, 
biocompatible feature and chemical properties
74
. Recently, CNT have been 
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proposed for biomedical applications such as cell tracking and labeling, tissue 
engineering scaffolds, nanosensors, and vehicles for controlled release of drugs 
or delivery of bioactive agents
65
.  
 
As mentioned, due to their multi-lineage differentiaton potentials and immune-
privileged characteristics, MSCs have become a feasible and potential source 
for tissue engineering applications
76
. It was also reported that CNT–derived 
patterned surfaces provides an ideal and suitable scaffolds for MSCs and neural 
stem cells
77, 78
. 
 
In addition to topographical features of scaffold material, the growth factors or 
small molecules which added into cell culture media are also important for 
tisseue engineering. Because, these factors support the attachment, proliferation 
and differentiaton of cells seeded onto biomaterial.  
 
1.4 ESTROGEN AND ESTROGEN RECEPTOR PATHWAY   
 
Estrogen, one of the steroid hormones, shows a wide variety of effects on 
growth, differentiation, sexual behavior, apoptosis, development, reproductive 
and cardiovascular functions and many physiological processes in female and 
male
79, 80
. Estrogen shows its effect in a broad range of tissues such as liver, 
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brain, bone, cardiovascular and reproductive systems
81
. The most dominant 
estrogen that found in human is 17β estradiol compared to estrone and estriol82.  
 
Estrogen does not only influence the differentiation, maturation and function of 
stem cells, but also have a proliferative and  antiapoptotic effect by changing 
the transcriptional activity of related genes
79,83
 . 
 
Nuclear receptors (NR) coordinately regulate the expression of genes that have 
a role in numerous of biological processes such as development, reproduction 
and homeostasis. NRs activate or repress gene transcription usually by binding 
to NR-specific ligands such as hormones, vitamins, lipid metabolites and 
xenobiotics
84
.  
 
Steroid hormone receptors are member of nuclear receptor family and act 
classically as transcription factors. Two major estrogen receptors; estrogen 
receptor alpha (ERα) and beta (ERβ), convey the regulatory signal of estrogen 
and control the transcription of target genes. ERs function both as signal 
transducer and transcriptional factor to regulate the target genes
85
. 
 
ERα (NR3A1 in human) was identified by Jensen and Jacobsen in 1962 and 
ERβ (NR3A2 in human) was identified in 1966 by Gustafsson in human, mouse 
and rat. Two receptors are encoded by different genes located on different 
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chomosomes. Moreover, any splice variant was not identified until now
86,87
. 
ERs share similar structural anatomy and sequence homology. An ER protein 
consists of six modular domains; N-terminal domain, which is called as A and 
B domains, is involved in transcriptional activation of target gene; DNA 
binding domain (C domain) enables the dimerization and binding of receptor to 
estrogen response element (ERE) on DNA; the hinge (D domain) is involved in 
receptor dimerization; C-terminal domain (E domain) is E2-binding domain; F 
domain modulates transcriptional activity of ER
88
. 
 
Two major ER pathways were identified so far; genomic or classical pathway 
and non-genomic pathway. In classical pathway, which is also called as 
estrogen response element (ERE) dependent pathway, estrogen hormone 
activates ER in the cytosol resulted in the formation of homodimer. Receptor 
translocates into to the nucleus after activation and homodimerization 
respectively and binds to estrogen response element (ERE), which is located at 
the promoter region of the target gene interacting with specific co-activators 
and co-repressors subsequently
82,83,89
. ERs localize in cytoplasm associating 
with heat shock proteins (Hsps) such as Hsp 90, Hsp 70, Hsp 56 in the absence 
of ligand. The Hsps maintain the estrogen receptors in inactive state. Binding of 
ligand to ERs trigger them to dissociate from Hsp and to dimerize
90
. The ER 
activation is generally stimulated in response to binding of 17-estradiol (E2) or 
other agonists; estrone (E1) and estriol (E3) in humans
82
. 
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In addition to classical ERE-dependent pathway, ERs can also regulate gene 
expression without direct binding to ERE on DNA. In this alternative pathway, 
ligand-activated ER associates with another transcription factor such as CRE-
like element, which binds to Jun/ATF transcription factors, AP-1 site, which 
binds to Jun/Fos transcription factor, and CCAAAT site, which binds to SP1 
and NF-Y transcription factors
88,90,91
, which, in turn regulates the transcription 
of genes that lack of ERE site. 
 
In the third form of genomic pathway, also referred to as ligand-independent 
pathway, growth factors are involved in process instead of estrogen. Nuclear 
ERs are phosphorylated by protein kinases such as ERK 1-2, p38 MAPK, 
cyclin dependent kinases, protein kinase A and Akt upon growth factor 
stimulation. Phosphorylated and activated ERs bind to ERE site of target genes 
91,92
. 
 
In the second major ER pathway, non-genomic pathway, numerous of signaling 
pathways such as mitogen-activated kinase (MAPK) pathway, PI3K/Akt 
pathway and JAK/STAT pathway are induced by estrogen-activated membrane 
bound ER
86
. The estrogen receptor signaling pathways were summarized in 
Figure 1.4. 
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Figure 1.4 Estrogen receptor signaling pathways 1. ERE-dependent classical 
pathway 2. ERE-independent genomic pathway 3. Ligand-independent genomic 
pathway 4.Non-genomic pathway  
 
 
 
1.5 EPIGENETICS 
 
 
Conrad Waddington came up with the term “epigenetic” 60 years ago. It is 
classically defined as stable alterations in gene expression that are mitotically 
and/or meiotically heritable and occur on DNA or chromatin structure without 
changing nucleotide sequence
93-95
.  Epigenetic modifications include reversible 
changes on given phenotype, but do not cause any change in genotype.  
Epigenetic mechanisms are master regulators of transcriptional pathways during 
major biological processes such as embryonic development, cellular memory, 
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cell and tissue specific gene expression, differentiation and adult tissue 
maintenance
96,97
. Gene regulation at the epigenetic level occurs through 
covalent modifications both on DNA and histones. These modifications 
regulate the gene transcription by opening chromatin structure (euchromatin), 
which enables the accessibility of transcription factors to activate gene 
expression, or facilitating condensed DNA structure (heterochromatin), which 
does not allow the entering of transcription factors to repress gene expression 
97,98
. Loosing of proper chromatin modifications cause lethality during 
embryonic developmental stage
99,100
. Epigenetic modifications despite of their 
stability can be reprogrammed using different strategies such as treatment with 
chemical compounds or hormones, transfection of transcription factors into the 
cells and nuclear fusion
98
. For instance, generation of iPS cells from somatic 
parental cells provided insight into epigenetic reprogramming of cells
102
. 
 
There are different kinds of epigenetic modifications such as DNA methylation, 
DNA hydroxymethylation, histone modifications, chromatin remodeling and 
microRNAs. However, DNA methylation and histone protein modifications are 
considered as two major epigenetic modifications involved in regulation of 
stem cell. 
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1.5.1 DNA METHYLATION 
 
The important role of DNA methylation/demethylation was first suggested by 
Griffith and Mahler in 1969
103
. DNA methylation is catalyzed by DNA 
methyltransferases (DNMTs) that add a methyl group (CH3) on 5’position of 
cytosine (m5C), which is at cytosine-phosphate-guanine (CpG) dinucleotides in 
some fungal, invertebrates, some bacteria species, flowering plants and in all 
vertebrates. DNA methyltransferases are conserved proteins and establish 
methylation at genes during in early development and cell division 
109,110
. 
Regions, which consist of high frequency of CpG residues, are defined as CpG 
islands
96,104
. CpG islands are located near the promoter regions of genes. 
According to computational analysis there are almost 29.000 CpG islands in 
human genome
105
.   
 
Epigenetic modifications can be widely reprogrammed in both germ cells and 
the preimplantated embryo. At two cell stages, the major genome-wide DNA 
methylation occurs in mammals; in primordial germ cells (PGC)  while 
migrating to genital ridge and after fertilization in embryo.  Early PGCs initially 
possess similar DNA methylation status to somatic cells. Upon fertilization, 
paternal and maternal genome is passively demethylated before replication and 
during replication respectively. After implantation, lineage specific de nova 
methylations which are catalyzed by two different DNMTs; DNMT3a, 
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DNMT3b. When PGCs enter into the genital ridge, the methylation is erased in 
response to signal from somatic cells in the gonadal anlagen
106,107
. De novo 
metylation occurs also in terminally differentiated somatic cells, but slower 
than embryonic cells and germ cells. Moreover, progressive global 
hypomethylation pattern on genomic DNA in somatic cells is associated with 
cancer and age
108,109
.  
 
Cytosine methylation is also associated with genomic imprinting and X-
inactivation, which is identified as completely silencing one of two identical 
alleles. Failure in imprinting of specific loci causes several disorders in human 
110,111,112
. During X-chromosome inactivation process, one of the two X 
chromosomes is randomly inactivated in female through dosage compensation 
mechanism and cytosine methylation 
109,110,113
. 
 
Methylated DNA associates with methly-CpG binding proteins (MBD) to 
repress gene expression. The major MBDs identified in mammalian are Mbd1, 
Mbd2, Mbd3, Mbd4 and MeCP2
114,115
. After binding to methylated CpG, 
MeCP2 recruits histone deactylases
116
, Mbd 1 recruits Suv39H1, which is a 
histone 3 lysine-9 (H3K9) methylase and HP1, which is a methyl lysine binding 
protein, respectively
117
 and Mbd2 and Mbd3 recruits NuRD, which is a ATP-
dependent nucleosome remodeling and histone deactelyase complex
118
.  
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The major question is that how epigenetic modifications can be propagated to 
daughter cells during cell division. DNA methylation pattern is maintained 
thanks to semi-conservative replication. DNMT1 enzyme provides the passing 
of methylation mark on the parental DNA strand to daughter cells during 
mitosis. On the other hand, de novo methylations both on hemimethylated and 
unmodified cytosines are catalyzed by DNMT3A and DNMT3B
111,119
.  
 
1.5.2 HISTONE MODIFICATIONS 
 
In eucaryotes, double-helix DNA is packaged by tightly wrapping 145-147 base 
pairs around an octomer. This DNA:protein compact structure is called as 
chromatin and nucleosome is the basic unit of chromatin. Nucleosome is 
composed of two copies of four core histone proteins; H2A, H2B, H3 and H4. 
In addition, histone protein H1 is a linker histone which establishes on DNA 
between nucleosomes and facilitates condensed nucleosome chain called as 
chromatin fiber
121
. Core histone protein stucture was shown in Figure 1.5. 
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Figure 1.5 Core histone structure (Figure is adopted from
194
) 
 
Packaging is required to establish the whole genomic DNA in nucleus. 
Dynamic N-terminal tails of histones, which protrude out from nucleosome 
structure, are subjected by post-translational modifications (PTMs). These 
modifications regulate gene transcription through controlling the accesibilty of 
transcription factors and co-regulators. There are eight major PTMs; 
methylation, acetylation, phosphorylation, ubiquitination, sumolaytion, 
deamination, ADP-ribosylation and proline isomerization. The modifications 
which occur on histone tails can be propagated to daughter cells during cell 
division like DNA methylation. Post-translational modifications occur on lysine 
(K), arginine (R), serine (S) and threonine residues of tails and they are 
regulated by specific enzymes termed chromatin modifiers. Furthermore, there 
are different forms of modifications that occur on these residues. For instance, 
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lysine residues can be mono-, di-, or trimethylated and one or two methyl group 
can be added to arginine residues 
96,118,120,121
.  
 
Genes are regulated by different combinations of histone modifications at a 
specific locus, which is known as histone code. Histone code hypothesis was 
firstly suggested by Strahl and Allis in 2000 
122,123
. 
 
Covalent modifications which take place on specific sites of histone tails 
associated with both activation and repression of transcription. Methylation of 
lysine 9 and lysine 27 of histone H3 (H3K9me / H3K27me) correlates with 
repression state, whereas methylation of lysine 4 or lysine 36 (H3K4me/ 
H3K36me) and acetylation of lysine 9  (H3K9ac) associates with active genes 
124,125
. Post-translational covalent histone modifications on core histone proteins 
was shown in Figure 1.6. 
 
First identified histone modifier enzyme was a histone acetyltransferase (HAT) 
Gcn 5
126
. HATs are considered as transcriptional activators because they 
provide the neuralization of positive charge of lysine via transferring acetyl 
group to ε amino group of lysine. Thus, they facilitated weakened DNA-histone 
interaction, which enables the access of transcription factors and co-activators. 
Histone deacetylases (HDACs) remove the acetyl groups from lysines and 
considered as repressors
127
. There are three main acetyltransferase families;  
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GNAT, MYST, and CBP/p300 and four classes of HDAC Classes I, II, IV and 
III, which is homologous to yeast Sir2
128
. 
 
 
Figure 1.6 Post-translational covalent histone modifications on core histone 
proteins. P: Phosphorylation, Ac: Acetylation, Ub: Ubiquitinylation, Me: 
Methylation (Figure is adopted from
118
). 
 
 
Histone methylation occurs on the lysine and arginine residues of tails. 
Methylation of lysines implies both active and repressive chromatin states
118
.  
Methylation of H3K9 and H3K27 associates with silent chromatin state, 
whereas methylation of H3K4 and H3K36 associates with euchromatin state
129
. 
In recent studies it was reported that, in mouse embryonic stem cells, bivalent 
domains are found which contain both H3K27me3 and H3K4me3 marks
130
. 
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SUV39H, which is the first identified histone lysine methyltransferase 
(HKMT), is responsible for the methylation of H3K9. HKMTs specifically 
methylate lysine residues at a specific degree; mono-, di-, tri- methylation
132,124
. 
SET7/9 catalayzes demethylaion of H3K4 and EZH2 targets H3K27. Histone 
modifier enzymes and modified residues were given in Table 1.2. 
 
Chromatin 
Modification 
Enzyme Modified Residues 
  HAT1 H4K5, H4K12, H3K14, H3K18      
  CBP300/P300 H4K5, H4K8, H2AK5, H2BK12, 
H2BK15     
ACETYLATION PCAF/GCN5 H3K9,H3K14,H3K18 
  TIP60 H3K14, H4K5, H4K12, H4K16, 
  SirT2 (ScSir2) H4K16 
  MLL1/2/3/4/5 H3K4 
  SUV39H2  H3K9 
 DEACETYLATION G9a  H3K9 
  ESET/SETDB1  H3K9 
  EZH2 H3K27 
  SET2 H3K36 
  SMYD1 H3K36 
 METHYLATION DOT1 H3K79 
  CARM1 H3R2,H3R17,H3R26 
  LSD1 H3K4 
  JHDM2a/b H3K9 
  JMJD3 H3K27 
DEMETHYLATION JHDM1a/b H3K36 
    
 
Table 1.2 Mammalian histone modification enzymes 
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1.6 EPIGENETIC ALTERATIONS IN STEM CELLS 
 
In ESCs, lineage specific genes are repressed through both DNA methylation 
and repressive histone modifications such as Histone-3 lysine-9 (H3K9) and 
Histone-3 lysine-27 (H3K27), whereas, the expressional regulation of 
pluripotency assocaited genes such as Oct4, Nanog and Sox2  is correlated with  
DNA methylation
110,131
. Moreover it was demonstrated that Polycomb group 
(PcG) protein complexes and HP1 are required for gene repression in ESCs
132
. 
Regulation of cell lineage speficic genes are mediated by bivalent histone 
modifications. Bivalent domains are considered as transcription-ready sites.  
These genes are regulated by both H3K4 and K27 trimethylation and the genes 
are activated upon differentiation induction
133
. Genome-wide distribution of 
DNA methylation, histone methylation and chromatin modifications regulates 
the changes that occur during cell differentiation. Thereby, epigenetic 
modification patterns including both histone modifications and DNA 
methylations of ESCs are clearly distinguished from differentiated somatic 
cells.  The genome-scale DNA methylation maps and chromatin-state maps of 
ESCs  revealed that housekeeping genes are highly expressed and enriched with 
H3K4me3 active mark, whereas lineage specific genes are repressed through 
both DNA methylation and repressive histone modifications such as H3K9 and 
H3K27
134
. DNA methylation is under the control of DNA methyltransferase 
Dnmt3a, Dnmt3b and Dnmt1 during embryogenesis
135
. A failure which changes 
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the maintenance of DNA methylation results in emryonic lethality in mice
136
 
and several diseases such as cancer, Alpha-thalassemia, mental retardation and 
fragile-X syndrome
112
. It was also reported that the passaging also causes 
change in DNA methylation pattern of ESCs.  In a previous study, it was 
demonstrated that methylation of tumor supressor genes; RASSF1, DCR1 and 
PTPN6 increase at late passages in human ESCs
138
.  
 
Direct reprogramming of somatic cells by transcription-factor transduction 
yields iPSCs with remarkable similarity to embryonic stem cells. These two 
pluripotent stem cells share very similar epigenetic profiles
137
. On the other 
hand large-scale methylation comparisons have identified differences such as 
CpG methylation which is higher in iPSC than in ESCs
138
. In addition whole-
genome screening revelaed the presence of differentially methylated regions 
(DMRs) within iPSC. These regionas are resistant to reprogramming
139
. 
Actually, the differences in pluriportent states and differential potential of iPCs 
and ESCs was not observed, whereas, retaining of the residual epignetic marks 
after differentiation influences cell fates in iPS cells. This problem manifests 
the epigenetic memory
140
. For instance, iPSCs derived neural progenitors and 
fibroblasts demonstrate decreased blood-forming potential in vitro due to the 
retained residual methylation at loci which is required for haematopoietic cell 
fate.  
In contrast to the promoters of pluripotent stem cells, most of genes specifying 
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cell types are hypomethylated in MSCs. DNA hypomethylation contributes 
transcriptionally permissive state. But this hypomethylated state does not 
predict differentiaton capacity of MSCs. Since these genes are mainly regulated 
by post-translational histone modifications. H3K4 and H3K27 bivalency on 
lineage-specific genes was demonstrated. After differentiation induction, 
H3K27 demethylases activates the transcription of these genes
5, 141
. In MSCs on 
adipogenic gene promoters including PPARγ2, leptin, fabp4, and lipoprotein 
lipase (lpl) hypomethylation is established. In addition the adipogenic genes 
show mosaic CpG methylation patterns
59
. During differentiation demethylation 
of H3K9, acetylation of H3 and H3K4 trimethylation were also shown on 
adipogenic gene promoters
142,143
.  MSC cultures from bone marrow show stable 
DNA methylation pattern between early and late passages. Osteocalcin is a 
ostegeneic linege specific gene and target of RUNX2. In the presence of 
osteogenic induction, on osteocalcin promoter acetylation of H3 and H4 
increases, wheras DNA metyhlation decreases
144
. It was known that 
osteogenesis has a dominant effect on adipogenesis and osteoblastic inducers; 
bone morphogenetic protein 2 (BMP2) and Wnt ligands, suppresses 
transcription of PPARγ recruting repressor histone methyltransferase145. It was 
also reported that JMJD2B and JMJD3B enzymes are the link between the 
osteogenesis and chondrogenesis. It was shown that overexperssion of these 
demethylases stimulates the expression of alkaline phospahatase (ALP), which 
is an osteoblast differentiation marker, whereas depletion of these demethylases 
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resulted in a significant increase in adipogenic differentiaton in MSCs
146
. 
 
1.7 ESTROGEN AND EPIGENETIC REGULATION 
 
  
 
Co-activators and co-repressors are directly recruited by nuclear receptors as a 
consequence of ligand-binding. Until now approximately 285 co-regulators 
associated with nuclear receptors were identified. Also it was reported that a 
mutation, which occurs in the expression of these co-regulators, causes diseases 
such as multiple cancers, Alzheimer, Parkinson and Huntington diseases
84
. 
Estrogen receptors also regulate gene transcription interacting with co-
activators or co-repressors; enzymatic complexes such as HATs, SWI/SNF 
complexes and HDACs
89
.  
 
Effect of estrogen on epigenetic mechanisms has been mostly investigated in 
breast cancers. In breast cancer, regulation of gene expression is mediated by 
methylation of DNA and acetylation of histone proteins and estrogen plays an 
important role in both formation of breast cancer and breast cancer treatment. It 
was well established that estrogen stimulates development of certain breast 
cancers and hormonal therapy via anti-estrogen treatment is widely used in 
treatment of these cancers
147
. H3K9me3 demethylase JMJD2B and H3K4 
methyltransferase MLL2 complex directly interacts with ER. This is 
responsible for the cellular function of ERα in MCF-7 breast cancer cell line148. 
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In the ER-negative breast cancer cells, promoter of ER gene is hypermethylated 
and ER mRNA is absent. Treatment of the ER-negative breast tumors with 
DNMT and HDAC inhibitors imposes to the reactivation of ERα149. 
 
In contrast to known stimulator effect of estrogen on gene expression, estrogen 
occupied ERα may also repress the gene expression by recruiting 
corepressor/HDAC complexes
150-153
 and DNA methyltransferase which enables 
establishment of hypermethylation on specific CpG loci
152
. On the other hand, 
high level of acetylation was observed on E2-stimulated genes. The proposed 
model was demonstrated in Figure 1.7. 
 
 
Figure 1.7  Demonstration of repression of early target genes mediated by ERα 
(Figure is adopted from
153
) 
 
CBP/p300, SRC-1 (NCoA-1/p160), SRC-2, SRC-3  are HATs that interact with 
36 
 
ER
154
. Recent studies have shown that in addition to lysine methyltransferases, 
arginine mehtyltransferases such as CARM1, PRDM1 and PRDM2 are also 
potential coactivators of ER
154
. Uterine growth in response to estrogen 
stimulation have demonstrated that PRDM2 directly binds to ER in the 
presence of estrogen. When ovariectomized mice were treated with estrogen, 
normal uterine horn growth was observed, whereas in PRDM2-null mutant 
mice the estrogen response was partially observed suggesting PRDM2 is 
required for maximal uterine response to estrogen
155
. 
 
Hippocampus is necessary for various types of memories such as relational, 
spatial and contextual information. Studies which focused on the relationship 
between hippocampus and epigenetic mechanism revealed that exogenous 
estrogen enhances hippocampus-dependent memory in ovariectomized rodents 
changing both histone H3 acetylation and DNA methylation
156
. 
 
1.7.1 RELATIONSHIP BETWEEN THE ROLE OF 
ESTROGEN IN EPIGENETIC REGULATION AND 
MESENCHYMAL STEM CELLS 
 
The effect of estrogen on MSC proliferation and differentiation into adiopocyte, 
osteocyte and chondrocyte have been shown in several studies
154-166
, MSCs are 
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potential cell source especially for tissue engineering applications due to their 
differentiaton capacities. The major obstacle was the limited isolated cell 
number of MSCs. It was reported that 17-β estradiol (E2) enhances effectively 
MSC proliferation in conventional cell culture media
80
. Moreover estrogen up-
regulates HTERT and telomerase activity. By this way, estrogen treatment 
prevents telomere shortening in MSCs
154-156
. Also, the inhibitory effect of 
estrogen on apoptosis through the expression of Bcl-2 family genes was 
demonstrated by our group
79
. Estrogen deficiency is considered as major cause 
of osteoporosis, osteoarthritis and obesity in postmenopausal women
88,89,156-158
. 
It was well established that estrogen promotes osteogenesis and 
chondrogenesis. Throughout life, bone tissue is remodeled by osteoblasts and 
osteoclasts which play key role in bone formation and bone resorption 
respectively. It was shown that estrogen treatment prevents the bone loss 
increasing the osteogenic differentiation activity in MSCs through ER α during 
postmenapausal stage
157
. In addition, estrogen is crucial for normal longitudinal 
growth. Further studies demonstrated that, estrogen replacement causes 
decreasing in vertebral deformation and loss of articular cartilage in 
postmenopausal women
158,159
.  
 
Obesity, which was defined as an excess amount of white adipose tissue 
accumulation resulted from increased adipocyte cell size, is considered as one 
of the top ten global health problems by World Health Organization
55, 160,161
. In 
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previous studies the existence of signal cross-talk between estrogen hormone 
and adipose tissue was also identified
162
. Both estrogen and phytoestrogen 
treatment represses adipogenesis inhibiting expression of early and late 
adipogenic differentiation markers
167,163
. The enhanced fatty acid formation in 
overieoctimized animals can be reversed by estrogen replacement therapy
162,164
.  
Studies have shown that, there is an inverse correlation between osteogenesis 
and adipogenesis. Differentiation of MSC into one lineage represses the 
differentiaton into another cell lineage
165
. Estrogen promotes osteogenesis and 
chondrogenesis in MSCs while inhibiting adipogenic differentitation through 
recruitment of co-repressors on the PPARγ and other adipose specific-genes 166.  
It was known that osteogenesis dominates the adipogenesis and bone 
morphogenetic protein 2 (BMP2) and Wnt ligands, which are 
osteoblastogenesis inducers, suppresses transcription of PPARγ through the 
activation of H3K9 methyl transferase SETDB1 and G9a
145,146
. 
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CHAPTER 2 
AIM OF THE STUDY 
 
Mesenchymal stem cells (MSCs) are considered as potential cell source for 
tissue engineering and regenerative medicine applications due to their multi-
lineage differentiation capacity, non-immunogenic characteristics, homing 
ability and easy isolation techniques. Moreover, until now different types of 
biomaterials were reported as scaffold material for MSC transplantation. In 
recent years, CNT was demonstrated as a new alternative scaffold material due 
to their unique physical properties such as injectable, cytocompatible features 
and nanoscale sizes. 
 
The key role of estrogen in the regulation of MSC proliferation, maintenance 
and differentiation is known. However, the effect of estrogen on the genetic and 
epigenetic regulation of MSC differentiation into specific cell types and on the 
maintenance of MSCs seeded on scaffold materials have not been fully 
elucidated.  
 
There is an inverse correlation between osteogenesis, chondrogenesis and 
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adipogenesis processes. Estrogen treatment stimulates osteogenesis and 
chondrogenesis while leads to the inhibition of adipogenesis in bone marrow 
stromal cells. Therefore, understanding the epigenetic and genetic mechanisms 
underlying MSC differentiation upon estrogen treatment and examination of 
cell viability and maintenance of MSCs on CNT biomaterial in the presence of 
estrogen may provide insight into the regulation of MSC-fate determination and 
increase our ability to use MSCs therapeutically.  
 
In this thesis, we aimed to study the genetic and epigenetic changes in 
transcription factors that regulate MSC differentiation with an emphasis on 
adipogenesis and osteogenesis upon estrogen treatment and the effect of 
estrogen hormone on the maintenance of MSCs on carbon nonatube arrays. 
 
The maintenance/viability of MSCs on CNT arrays at different passages were 
assessed in the presence and absence of estrogen. In addition we also tested 
whether CNTs could replace the presence of extracellular matrix by culturing 
them without collagen. 
 
The effect of estrogen on the expression and differential localization of 
transcription factors involved in adipogenesis, osteogenesis and chondrogenesis 
differentiation of MSCs were examined. In addition, estrogen’s effect on the 
histone modifications and histone modifier enzymes were investigated. 
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Promoter regions of adipogenic and osteogenic transcription factors were 
examined for possible binding of Erα. CpG methylation status of adipogenic 
transcription factors and ERα were also investigated upon estrogen treatment. 
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1  ANIMALS  
 
For the experiments, normal female and ovariectomized Sprague Dawley rats 
were used. The animals were kept in the animal holding facility of the 
Department of Molecular Biology and Genetics at the Bilkent University 
permitting unlimited access to food and water at all times .The animals were 
housed under controlled environmental conditions with 12 hour light and 12 
hour dark cycles and at 22˚C. The experimental protocols were performed 
according to Bilkent University’s guidelines on humane care and use of 
laboratory animals.  
 
3.1.1 OVARIECTOMIZATION 
 
The ovariectomization procedure was performed under full anesthesia using 
Ketamine (Park Davis, Michigan, USA) at a concentration of 30 mg/kg. On the 
vertebrate two incisions were made. Ovaries which are at the tip of each uteri 
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horn were tied with silk and removed. The incisions were sutured and kept 
under control until animals recovered from the anesthesia. Ovariectomized 
animals were used for experiments almost after 2 months after the operation to 
ensure the total deficiency of estrogen. 
 
3.2 SYNTHESIS, PATERNING CHARACTERIZATION OF 
CARBON NANOTUBES 
 
 Carbon nanotubes (CNT) were prepared by Assist. Prof. Dr. Erman Bengü and 
Gökçe Küçükayan in Bilkent University, Department of Chemistry. In this 
study multi-walled type carbon nanotube (CNT) samples were used. The 
vertically aligned carbon nanotubes arrays were synthesized performing 
chemical vapor deposition (ACCVD) method on Si substrates. The catalyst 
layers were formed on the Si surface using sandwich catalyst design; Al:Co:Al 
as reported in previous study
167
. The aforementioned layers were introduced 
into the ACCVD furnace for growth of carbon nanotube. Asperities were 
created on vanta surfaces in patterning step. For this purpose, deinozied water 
was dropped on the vanta surfaces to form cavities resulting of water contact. 
After the synthesis and patterning steps, characterization of syhtnesized CNTs 
was done using scanning electron microscope (SEM) analysis was performed 
by Assist. Prof. Dr. Erman Bengü and Gökçe Küçükayan in Bilkent University, 
Department of Chemistry.  
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To examine the effect of collagen on the attachment and cell viability, patterned 
CNTs were also treated with 2.5 µl of 1 µg/µl sterilized collagen solution. 
Collagen coated and non-coated CNT layers were sterilized under UV for 45 
minutes before using in cell culture.  
 
 3.3 ISOLATION AND CULTURING OF MSC FROM RAT 
BONE MARROW  
 
Bone marrow heterogeneous cell population was collected from the tibia and 
femur of the normal female and ovariectomized nine-week old, 280-300 g 
Sprague-Dawley rats. After cervical dislocation, tibia and femur bones were 
removed and bone marrow cells were flushed with a 5 mL syringe in DMEM 
(HyClone, Logan, USA) containing 10% fetal bovine serum (FBS) (HyClone, 
Logan, USA) and 1% penicllin-streptomycin antibiotic (HyClone, Logan, 
USA). The cell suspension was centrifuged at 1500 rpm for 5 minutes and the 
supernatant was removed. Cell pellet was resuspended in 10 ml of 1X 
phosphate buffered saline (PBS) and then centrifuged again at 1500 rpm for 5 
minutes. The washing step was performed two more times with the same 
conditions.   The bone marrow cells were cultured in MesenCult medium 
(StemCell Technologies, Vancouver, Canada) including 20% supplement 
(StemCell Technologies, Vancouver, Canada) and a 1% penicillin–
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streptomycin solution (HyClone, Logan, USA) for fourteen days to obtain 
mesenchymal stem cell. The equal number of cells was plated onto the cell 
culture flasks. The cells were counted with hematocytometer and calculation 
was done according to formula given below:  
Total number of cells = number of cells in mm
3 
X 10
4 
X dilution factor 
 
The media were changed every 4 days, after washing with sterile 1XPBS. In 
addition to untreated group, for treatment either 10
-7
 M estrogen (17 ß-estradiol, 
Sigma, Germany) or 10
-6 
M
 
tamoxifen (Sigma, Germany) was added to the 
culture plates from the first day of culture and until the last day to obtain the 
estrogen or tamoxifen treated counterparts. Tamoxifen treated groups were used 
for chromatin immunoprecipitation experiments.  
 
To investigate the role of estrogen in the maintence of MSCs on CNTs, at the 
end of the 14th day, 10
4
 cells which were incubated in the absence and presence 
of the estrogen were seeded on non-coated CNT surfaces. The cells were 
incubated cultured on CNTs for 3 days.  
 
In addition, to examine the changes of cell viability and growth of MSCs on the 
collagen coated and non-coated CNTs, cells were passaged when they reach 
confluency. The groups were stated as passage zero (P0), passage 1 (P1) and 
passage 2 (P2). After each passage, 10
4
 cells were seeded on patterned CNT 
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placed in 96-well plates to measuere cell viability and 3 x10
5
 cells were seeded 
on patterned CNT placed in 6-well plates to count the number of cells. MSCs, 
which were seeded on to 96-well culture plates without CNT arrays, were used 
as control group.  
 
3.4 IMAGING OF MSCS ON CARBON NANOTUBES 
 
The CNTs were placed in 6-well plates. 3x10
5
 MSCs from P0, P1 and P2 were 
cultured in Mesencult media on the CNTs. The cells were washed with 1XPBS 
at the end of the 3
rd
 day of culture and their image was taken by SEM at low 
vacuum mode. 
 
3.4.1 CALCULATION  OF THE NUMBER OF ATTACHED 
MSCS ON CNT SURFACES 
 
3x10
5
 MSCs from P0, P1 and P2 were seeded onto non-coated and collagen 
coated patterned CNT surfaces. At the end of the 3
rd
 day of incubation, SEM 
analysis was performed. The number of attached cells were counted from the 
SEM images and average areal density was calculated by dividing this number 
to the total surface area. 
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3.4.2 CELL PROLIFERATION ASSAY FOR THE MSCS ON 
CNT SURFACES 
 
The viability of MSCs on the coated and non-coated CNTs were examined by 
cell proliferation assay (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-tetrazolium 
bromide- MTT) using Cell Proliferation Kit I (Roche). 10
4
 cells were seeded 
onto patterned CNTs in 96-well culture plates. At the end of the 3
rd
 day of 
incubation, MTT assay was performed according to the manufacturer’s 
instructions. Control group was obtained from cells seeded onto 96-well culture 
plates without CNT arrays and their viability was accepted as 100%. 
Spectrophotometrical absorbance of the samples was measured by ELISA 
reader with the wavelength between 550 and 600 nm. 
 
3.5 ADIPOGENIC AND OSTEOGENIC DIFFERENTIATION 
 
MSCs were trypsinized (Hyclone, Logan, USA) and plated onto new cell 
culture flasks at day 14 of their culture and incubated with Mesencult media 
until they reached 85-95% confluency. After that, the media was replaced with 
adipogenic induction media containing 100 μM indomethacine 
(Sigma,Germany), 1 μM dexamethasone (Sigma,Germany), 0.5mM IBMX 
(Sigma,Germany), 10 μg/mL insulin (Sigma,Germany), 1% 
penicillin/streptomycin (HyClone,Logan, USA), 10% FBS (HyClone, Logan, 
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USA) in DMEM-LG (HyClone Logan, USA) and osteogenic induction media 
containing 0.1 µM dexamethasone, 10 mM glycerol phosphate salt hydrate 
(Sigma,Germany), 0.2 mM ascorbic acid γ-irradiated (Sigma,Germany), 10 % 
FBS (Hyclone, Logan, USA) and 1% penicillin/streptomycin (Hyclone Logan, 
USA) in DMEM low glucose (Hyclone, Logan, USA). The media was changed 
three times a week. Adipogenic and osteogenic induction media were prepared 
freshly before every medium change. As negative control, the cells were 
incubated only with DMEM low glucose (Hyclone, Logan, USA) for 24 days in 
the presence and absence of estrogen.  
 
3.6 DETECTION OF ADIPOGENIC AND OSTEOGENIC 
INDUCTION 
 
3.6.1 OIL RED O STAINING   
 
At the end of the 13
th
 day and 24
th
 day of the adipogenic differentiation, the 
medium was removed and cells were washed with 1XPBS. They were 
incubated in 10% formaldehyde for 10 minutes at room temperature (RT) and 
washed once with 1XPBS and then with water. Cells were incubated with Oil 
red O (Sigma, Germany) solution for 50 minutes at room temperature. 
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Afterwards, Oil red O solution was aspirated and the cells were washed with tap 
water. The photos were taken under the light microscope. 
 
3.6.2   ALIZARIN RED STAINING 
 
 At the end of the 13th day and 24th day of the osteogenic differentiation, the 
media was aspirated and cells were washed with 1XPBS. Then they were fixed 
with 70% ethanol at room temperature for 1 hour. After that the cells were 
washed with distilled water and stained with 40 mM Alizarin Red S (Sigma, 
Germany) (pH:4.1) at room temperature for 30 minutes. The cells were washed 
with tap water. Photos were taken under light microscope. 
 
3.7   TOTAL RNA ISOLATION FROM MSCs AND 
DIFFERENTIATED CELLS  
 
Total RNA was isolated from MSCs at the end of the 14
th
 day of the cell culture 
and from adipogenic and osteogenic differentiated cells at the end of the 13
th
 
day, 17
th
 day and 24
th 
day of the differentiation. The cells were washed with 
1XPBS twice and trypsinized (Hyclone, Logan, USA) at 37˚C for 3 minutes. 
The cells were collected from cell culture flasks adding DMEM (Hyclone , 
Logan, USA) containing 10 % FBS (Hyclone Logan, USA) and 1% penicilin-
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streptomycin (Hyclone, Logan, USA). The cell suspension was centrifuged at 
1500 rpm for 5 minutes. After centrifugation supernatant was sucked and pellet 
was resuspended in 10 ml 1XPBS to wash and centrifuged again at 1500 rpm 
for 5 minutes. The supernatant was removed. The cell pellet was used for RNA 
isolation using Nucleospin RNA II kit isolation kit (Macherey-Nagel, Germany) 
according to instructions of the manufacturer.  At the end of the protocol RNA 
was eluted with RNase free water and the concentration was determined with 
NanoDrop ND1000 spectrophotometer (Nanodrop technology, USA).  
 
3.8    cDNA SYNTHESIS 
 
For each cDNA synthesis reaction 2 μg of RNA was used by using DyNAmo 
cDNA synthesis kit (Finnzymes, Finland). 2 μg RNA was mixed with DEPC 
treated ddH2O to a total volume of 12 μl. 2 μl of Oligo (dT) primer was added 
to the mixture. The mixture was incubated at 65˚C for 5 minutes and then 
chilled on ice for 3 minutes. 20 μl of 2X RT buffer including dNTP mix and 
MgCl2, and 4 μl of M-MuLV RT RNase H+ enzyme was added to the mixture 
and then incubated at 25˚C for 10 minutes, 45˚C for 45 minutes and 85˚C for 5 
minutes. The cDNA samples were kept at -20˚C. 
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3.9   PRIMER DESIGN FOR QUANTITATIVE REAL TIME 
PCR AND REVERSE TRANSCRIPTASE PCR 
 
Primers which were used for quantitave real time PCR (qRT-PCR) and reverse 
transcriptase PCR (RT-PCR) were designed by using Primer exe, Primer3 and 
Primer Blast (NCBI) programs. The amplified fragment size of the PCR 
products of each primer and the specificity of the primers were controlled with 
NCBI and ENSEMBLE databases which are publicly available. The primer 
sequences were listed in the Table 3.1 
 
 
3.10 QUANTITATIVE REAL TIME PCR 
 
The real time PCR reactions were performed using SYBR green real time PCR 
kit (Finnzymes, Finland) at a reaction volume 12.5 µl containing 6.25 µl of 
SYBR green master mix, 1µl 10 pmol forward, 1µl of 10 pmol reverse primers, 
3.25 µl  of ddH2O, 1 µl of cDNA. Cyclophilin was used as a housekeeping gene 
and expression results for all transcription factors were normalized according to 
Cyclophillin expression level. Before performing qRT-PCR reactions using 
experimental samples, amplification efficiencies for all primers were calculated 
by using 1:2 dilution series according to the below formula:  
             Efficiency = 2^ (-1/slope) 
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Fold changes in the expression of the genes were analyzed based on the 
comparative (2
-ΔΔCt
) method. Normal female MSCs were used as calibrator. The 
qRT-PCR reaction conditions for all investigated genes were given in the Table 
3.2. Each protocol was followed by melt curving to control purity of the 
amplification. Efficiencies of primers were stated in Table 3.3. 
 
 
3.11 REVERSE TRANSCRIPTASE PCR  
 
DNA amplification for adipogenic transcription factors; C/EBPα, FABP4, 
PPARγ and osteogenic transcription factor; RUNX2 were performed using 
Phire Hotstart Taq Polymerase (Finnzymes, Finland). Taq DNA Polymerase 
was used for β-actin amplification. The MSCs seeded onto CNTs were 
characterized by using CD90, CD70, CD45, CD34 and CD29 markers. For 
characterization experiment, RT-PCR was performed using Taq Polymerase 
(Finnzymes, Finland). RT-PCR conditions were given in the Table 3.4. 
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Name of the 
Genes Sequences of Forward and Reverse Primers     Size (bp) 
CEBP α forward 5'-AGTCGGTGGATAAGAACAGC-3' 118 
  reverse 5'-CATTGTCACTGGTCAACTCC-3'   
PPAR γ forward 5’-TTTTCAAGGGTGCCAGTTTC -3’ 178 
  reverse 5’-AATCCTTGGCCCTCTGAGAT-3’   
FABP4 forward 5'-CACCGAGATTTCCTTCAAAC-3' 136 
  reverse 5'-TCACCATCTCGTCTCCTCTT-3'   
Adipsin forward 5’-TGGTGGATGAGCAGTGGGT -3’ 110 
  reverse 5’-AGGGTTCAGGACTGGACAGG- 3’   
RUNX2 forward 5'-TAACGGTCTTCACAAATCCTC -3' 115 
  reverse 5-'GGCGGTCAGAGAACAAACTA -3'   
SOX9 forward 5'-GTGGATGTCAAAGCAACAGG-3' 168 
  reverse 5'-TCTTGATGTGCGTTCTCTGG-3'   
ATF3 forward 5'-ACAACAGACCTCTGGAGATG-3' 120 
  reverse 5'-CAGGCACTCTGTCTTCTCTT-3' 
 MEF2C forward 5'-TTGAGTAGAAGGCAGGGAGA-3' 107 
  reverse 5'-CAGCAGCAGCACCTACATAA-3' 
 ETS1 forward 5’-CCCTGGTAACGTGCAGAAGT-3 158 
  reverse 5’-CTTCCAGATGTCCAGGTGAG-3 
 Cyclophilin forward 5’-GGGAAGGTGAAAGAAGGCAT-3’ 211 
  reverse 5’-GAGAGCAGAGATTACAGGGT-3’ 
 CD90 
 
forward  5’- CCAGTCATCAGCATCACTCT-3’ 
reverse   5’- AGCTTGTCTCTGATCACATT- 3’ 
374 
CD34 forward  5’- TGTCTGCTCCTTGAATCT -3’ 
reverse   5’- CCTGTGGGACTCCAACT- 3’ 
281 
CD29 forward  5’-ACTTCAGACTTCCGCATTGG -3’ 
reverse  5’- GCTGCTGACCAACAAGTTCA-3’ 
190 
CD45 forward 5’- ATGTTATTGGGAGGGTGCAA-3’ 
reverse  5’- AAAATGTAACGCGCTTCAGG-3’ 
175 
CD71 forward 5’- ATGGTTCGTACAGCAGCAGA-3’ 
reverse  5’- CGAGCAGAATACAGCCATTG-3’ 
182 
BETA ACTIN forward 5’-CTGGCCTCACTGTCCACCTT-3’ 
reverse 5’-GGGCCGGACTCATCGTACT-3’ 
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Table 3.1 The product size and sequences of primers used for qRT-PCR 
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Name of the 
Genes 
First 
Denaturati
on 
Denaturation Annealing Extension Cycle 
Final 
Extension 
CEBPα 
95°C, 15 
min 
 
94°C, 30 sec 60°C, 60 sec 72°C, 40 
sec 
30 72°C, 50sec 
FABP4 
95°C, 15 
min 
 
94°C, 30sec 60°C, 60 sec 72°C, 40 
sec 
30 72°C, 50sec 
PPARγ 
95°C, 15 
min 
 
94°C, 30sec 60°C, 45 sec 72°C, 45 
sec 
30 72°C, 50sec 
RUNX2 
95°C, 10 
min 
 
94°C, 30 sec 60°C, 45 sec 72°C, 40 
sec 
30 72°C, 50sec 
SOX9 95°C, 10 
min 
94°C, 30 sec 63º C,60sec 72°C, 20 
sec 
30 72°C, 50sec 
ATF3 95°C, 10 
min 
 
94°C, 30 sec 64º C,45sec 72°C, 20 
sec 
30 72°C, 50sec 
MEF2C 95°C, 10 
min 
 
94°C, 30 sec 64º C,45sec 72°C, 20 
sec 
30 72°C, 50sec 
ETS 95°C, 10 
min 
 
94°C, 30 sec 64º C,45sec 72˚C, 
20sec 
30 72°C, 50sec 
Adipsin 95°C, 15 
min 
 
94°C, 30 sec 60º C,45sec 72°C, 20 
sec 
30 72°C, 50sec 
Cyclophillin 95°C, 15 
min 
94°C, 30 sec 
 
55º C,45sec 
 
72°C, 20 
sec 
30  72°C, 
50sec 
 
 
Table 3.2 qRT-PCR conditions 
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Name of the Genes Efficiency 
CEBP α 2.1 
PPAR γ 2.2 
FABP4 1.7 
Adipsin 2.08 
RUNX2 2.1 
SOX9 2.2 
ATF3 1.9 
MEF2C 2 
ETS1 2.2 
Cyclophillin 1.9 
 
Table 3.3 Efficiencies of primers used for qRT-PCR 
 
 
Name of 
the 
Genes 
First 
Denaturation Denaturation Annealing Extension Cycle 
  Final 
Extension 
CEBPα 
98°C, 30 sec 98°C, 5 sec 63°C, 60 sec 72°C, 40 sec 35 72°C, 50sec 
FABP4 
98°C, 30 sec 98°C, 5 sec 63°C, 60 sec 72°C, 40 sec 35 72°C, 50sec 
PPARγ 
98°C, 30 sec 98°C, 5 sec 60°C, 45 sec 72°C, 40 sec 35 72°C, 50sec 
RUNX2 
98°C, 30 sec 98°C, 5 sec 60°C, 45 sec 72°C, 40 sec 35 72°C, 50sec 
β actin 
95°C, 30 sec 95°C, 30 sec 60°C, 35 sec 72°C, 40 sec 25 72°C, 50sec 
CD90 
95°C, 5 min 94°C, 30 sec 55°C, 30 sec 72°C, 30 sec 30 72°C, 5 min 
CD34 
95°C, 5 min 94°C, 30 sec 55°C, 30 sec 72°C, 30 sec 30 72°C, 5 min 
CD71 
95°C, 5 min 94°C, 30 sec 66°C, 60 sec 72°C, 45 sec 35 72°C, 5 min 
CD29 
95°C, 5 min 94°C, 30 sec 60°C, 30 sec 72°C, 30 sec 26 72°C, 5 min 
CD45 
95°C, 5 min 94°C, 30 sec 60°C, 30 sec 72°C, 30 sec 45 72°C, 5 min 
 
Table 3.4 RT-PCR conditions 
 
 
3.12 AGAROSE GEL ELECTROPHORESIS 
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1XTAE was used to prepare 1% agarose gel and 1 mg/ml ethidium bromide 
was added to agarose-TAE mixture prior to polymerization. Before loading the 
samples onto the gel, 6X agarose gel loading dye was added to the PCR 
products at a final concentration of 1X. Gene ruler DNA ladder mix 
(Fermentas, Canada) and 100 bp DNA Ladder (New England, Biolabs, MA, 
USA) was used as markers and 5 µl was loaded to gel.  The gel was run at 85 
Volt for 25-40 minutes and visualized under transluminator (Gel-Doc Biorad 
Vilber Lourmat, France). ChemiCapt (Vilber Lourmat) software was used to 
take the photographs of the gel. 
 
 3.13 SEMI QUANTITATIVE ANALYSIS 
 
 After the gel photos were taken, semi quantitative analysis for RT-PCR results 
was performed using Bio1D (Vilber Lourmat) to calculate the band intensities. 
 
3.14 IMMUNOFLUORESCENCE STAINING FOR 
TRANSCRIPTION FACTORS 
 
At the end of the 14
th
 day of culture MSCs were trypsinized and 1.5x10
5
 cells 
were seeded onto cover slips (Deckglaser 100 No.1 12mm) in the 6-well cell 
plates. They were fixed with ice-cold methanol for 10 minutes. The cells were 
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washed with 1X PBS-Tween solution twice and left in blocking solution for 1 
hour at room temperature. After that, blocking solution was removed and the 
cells were incubated with primary antibodies for 1 hour at room temperature.  
All primary antibodies were purchased from Santa Cruz (Santa Cruz, USA). 
After primary antibody incubation, cells were washed twice with 1XPBS-
Tween and incubated with FITC-labeled secondary antibodies for 1 hour at 
room temperature.  All secondary antibodies were purchased from Santa Cruz 
(Santa Cruz, USA). Finally, after the secondary antibody incubation, cover slips 
were washed twice with 1XPBS-Tween solution and mounted with mounting 
medium containing DAPI (Santa Cruz). The images were captured by 
fluorescent microscope with 490 nm and 359 nm wavelengths for FITC and 
DAPI respectively. Primary and secondary antibodies used in 
immunofluorescence staining and their dilution concentrations were stated in 
Table 3.5. 
Antibody Dilution 
PPAR g  1:200 
Ets1  1:200 
FITC-Anti Rabbit  1:200 
FITC-Anti Mouse  1:200 
                     
Table 3.5 Dilution rates of antibodies used for immunofluorescence staining 
 
 
 
3.15 PROTEIN ISOLATION AND QUANTIFICATION 
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3.15.1 TOTAL PROTEIN ISOLATION AND 
QUANTIFICATION 
 
 MSCs were scraped from cell culture flasks in 10ml 1XPBS with a scraper. 
Cell suspension was centrifuged at 1500 rpm for 5 minutes at 4˚C. The pellet 
was dissolved in lysis buffer and incubated on ice for 30 minutes by finger 
tipping every 5 minutes. Then, the lystes were centrifuged at 13000 rpm for 20 
minutes at 4˚C. Supernatant containing total proteins was taken and stored at -
80˚C. The protein concentration was determined performing Bradford assay168.  
  
 
 
3.15.2 HISTONE PROTEIN EXTRACTION FROM MSCs 
 
At the end of the 14th day, MSCs were scraped and cell pellet was dissolved in 
400 µl TEB buffer containing 1XPBS, 0.5% Triton X-100 (Sigma, St. Louis, 
Germany), 0.02% NaN3 (Merck, Darmstadt, Germany), 1X Protease inhibitor. 
Samples were centrifuged at 2000 rpm for 10 minutes at 4°C and supernatant 
was removed. Cell pellet was resuspended in 200 µl the TEB buffer and 
centrifuged again at 2000 rpm for 10 minutes at 4°C. The pellet was dissolved 
in 150 µl 0.2N HCL and incubated at 4°C with rotating for over-night. Samples 
were centrifuged at 2000 rpm at 4°C for 10 minutes and supernatant containing 
histone proteins was collected. Samples were kept -80˚C. 
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3.15.3 CYTOPLASMIC AND NUCLEAR PROTEIN 
EXTRACTION FROM MSCs 
 
Nuclear and cytoplasmic protein isolation was performed using NE-PER 
Nuclear and Cytoplasmic Extraction Reagents according to manufacturer’s 
protocol (Thermo Scientific, USA). MSCs were trypsinized (Hyclone, Logan, 
USA) and collected in 1.5 ml microcentrifuge tube. After centrifugation at 500 
g for 3 minutes, the pellet was mixed with 200 µl of CER 1 and 11 µl of CER 2 
solutions respectively. By centrifugation at 16000 g for 5 minutes, supernatant 
including cytoplasmic extract was removed and kept. The pellet was dissolved 
in 100 µl of NER solution and after centrifugation at 16000 g for 10 minutes, 
supernatant including nuclear extract was removed. Extracted proteins were 
kept at -80 °C. Primary and secondary antibodies used for western blotting after 
and their dilution concentrations were listed in Table 3.6. 
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Antibody Blocking Solution Dilution 
PPAR gamma   5% milk powder in 0.3% TBS-T  1:250 
Ets1 5% milk powder in 0.3% TBS-T  1:250 
Atf3 5% milk powder in 0.3% TBS-T  1:250 
Calnexin 5% milk powder in 0.3% TBS-T  1:1000 
Cyclin E1 5% milk powder in 0.3% TBS-T  1:200 
H3K27me2 5% BSA in 0.1% TBS-T  1:500 
H3K27me3 5% BSA in 0.1% TBS-T  1:500 
H3K9me2 5% BSA in 0.1% TBS-T  1:750 
H3K9me3 5% BSA in 0.1% TBS-T  1:750 
H3K36me3 5% BSA in 0.1% TBS-T  1:750 
EZH2 5% BSA in 0.1% TBS-T  1:750 
LSD1 5% BSA in 0.1% TBS-T  1:750 
SET 7/9 5% BSA in 0.1% TBS-T  1:750 
H3 5% BSA in 0.1% TBS-T  1:750 
CD29 5% milk powder in 0.3% TBS-T 1:250 
CD34 5% milk powder in 0.3% TBS-T 1:500 
Actin 5% milk powder in 0.3% TBS-T 1:1000 
HRP-Anti Rabbit 5% milk powder in 0.3% TBS-T  1:2500 
HRP-Anti Mouse 5% milk powder in 0.3% TBS-T  1:2000 
HRP-Anti Goat 5% milk powder in 0.3% TBS-T  1:5000 
 
Table 3.6 Primary and secondary antibodies used in western blotting and their 
dilution rates in blocking solutions.  
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3.17   WESTERN BLOTTING 
3.17.1 SDS- POLYACRYLAMIDE GEL ELECTROPHORESIS 
 
The protein samples were resolved by SDS-PAGE gel with 15% (for histone 
proteins) and 10% (for cytoplasmic and nuclear proteins) separating gel and 5% 
stacking gel. 30 μg protein sample for the cytoplasmic-nuclear extracted 
proteins and 5-10 μg samples for the histone proteins were used. The protein 
samples were mixed with 2% cracking buffer including 10% β-
mercapthoethanol (Sigma, St. Louis, USA) and boiled at 95˚C for 10 minutes 
for denaturation. 24 µl of the denaturated protein samples and 7 µl of the 
prestained protein marker (Fermentas, Canada) were loaded on the gel and run 
at 85 V. The running was terminated when the marker was seperated enough to 
detect the required range of weight. 
 
3.17.2 TRANSFER OF THE PROTEINS TO PVDF 
MEMBRANE 
 
3.17.2.1 SEMI-DRY TRANSFER 
 
Proteins in the range of 20-75 kDa were transferred by semi dry transfer 
method to a polyvinylidene fluoride membrane (PVDF) (0,45 μm, Thermo 
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Scientific, MA, USA). Beforehand, PVDF membrane was put in methanol for 
20 seconds for activation and then washed in ddH2O for 2 minutes to remove 
the excess methanol. 4 whatmann papers which were cut according to the size 
of the gel and membrane were put into semi-dry transfer buffer. The gel was 
washed with ddH2O and the stacking part was cut and removed. Seperating part 
of the gel was soaked in semi dry transfer buffer almost 3 minutes. Gel, 4 
whatmann papers and PVDF membrane were placed onto the semidry transfer 
apparatus (Bio-Rad, CA, USA) at a specific order of; 2 whatmann papers, 
PVDF membrane, gel and 2 whatmann papers. Transfer was performed with a 
current of 3,5 mA/cm
2
 membrane for 45 minutes. The gel was stained with 
comassie brilliant blue for 30 minutes and destained with destaining solution 
for over night to control the transfer of the proteins from the gel to the 
membrane.  
 
3.17.2.2 WET TRANSFER  
 
The histone proteins are smaller than 20 kDa. Therefore wet transfer method 
was performed. Firstly, PVDF membrane was put in methanol for 20 seconds 
for activation and then washed in ddH2O for 2 minutes to remove the excess 
methanol. 4 whatmann papers and 2 sponges were soaked into the 1X wet-
transfer buffer prepared for small proteins. The gel was washed with ddH2O 
and the stacking part was cut. Seperating part of the gel was soaked in wet 
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transfer buffer almost 3 minutes. The proteins were transfered at 40V and for 
2,5 hours at +4˚C within BioRad gel tank (Bio-Rad, CA, USA). The gel was 
stained with comassie brilliant blue for 15 minutes and destained with 
destaining solution for over night to control. 
 
3.17.2.3 IMMUNOLOGICAL DETECTION OF THE 
PROTEINS 
 
After the transfer of the proteins to membrane, membrane was blocked with the 
blocking solution as indicated in Table 3.5 for different antibodies for 2 hours. 
After the blocking, the membrane was left in primary antibodies for incubation 
at 4˚C for over-night on shaker (RotaMix, Thermolyne, IA, USA). The primary 
antibodies were diluted in block solution at various concentrations as given in 
Table 3.6 H3 was used as loading control of histone modification protein. 
Cyclin E1 and Calnexin were used to check cytoplasmic-nuclear seperation of 
proteins in MSCs. The following day, the membrane was washed 3 times for 10 
minutes with 1XTBS-(0.3%) Tween solution and incubated on shaker for 1 
hour at RT with the related horseradish peroxidase (HRP) secondary antibodies 
listed in the Table 3.5. Subsequently the membrane was washed for 3 times for 
10 minutes with 1XTBS-(0.3%) Tween. Chemiluminescence was detected 
using the Super Signal West Femto Maximum Sensitivity Substrate (Thermo 
Scientific, IL, USA) for 1.5 min and developed.  
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Histone antibodies were purchased from Cell Signaling (Danvers, MA, USA), 
HRP conjugated secondary antibodies and PPARγ, ETS1, RUNX2, SOX9, 
MEF2C, ATF3, Actin, Calnexin, CD29 and CD34 antibodies were purchased 
from Santa Cruz (Santa Cruz, CA, USA). The band intesties of histone 
modifications proteins were calculated. The photographs of X-ray films were 
taken under transluminator (Gel-Doc Biorad Vilber Lourmat, France). 
ChemiCapt (Vilber Lourmat, France) software was used to take the 
photographs of the developed films.  After the photos were taken, the band 
intensities were calculated using Bio1D (Vilber Lourmat, France). Protein 
expression results for all modified histone proteins were normalized to H3 
expression.  
 
3.18 CHROMATIN IMMUNOPRECIPITATION (ChIP) 
ASSAY 
 
3.18.1 IN VIVO CROSSLINKING AND DIGESTION OF 
CHROMATIN 
 
The assay was performed using SimpleChIP Enzymatic Chromatin IP Kit 
Agarose Beads (Cell Signaling Technology, USA) according to manufacturer’s 
protocol. Without sucking the media, 40% fresh formaldehyde was added in 
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cell culture plates at the end of the 14
th
 day of the cell culture to crosslink 
proteins to DNA. Final formaldehyde concentration was 1% in media. Culture 
plates were swirled briefly and incubated at room temperature for 10 minutes. 2 
ml of 10X glycine was directly added to each plate and mixed by swirling the 
plate briefly. Cells were incubated for 5 minutes at room temperature. After that 
media containing formaldehyde and glycine was completely removed and cells 
were washed two times with 20 ml ice-cold 1X PBS. 2ml ice-cold 1X PBS + 
PMSF solution was added into each culture plate and cells were scraped into 
this cold buffer. Cells in 3 plates were combined into one 15 ml canonical tube 
and centrifuged at 1.500 rpm for 5 minutes at 4˚C. Supernatant was removed. 
Cells were resuspended in 4 ml ice-cold Buffer A+DTT+Protease inhibitor 
cocktail (PIC) + PMSF solution and incubated on ice for 10 minutes by 
inverting tube every 3 minutes. After centrifugation at 4°C for 10 minutes at 
3000 rpm supernatant was removed and pellet was resuspended in 4 ml ice-cold 
buffer B+DTT. Centrifugation was repeated and sample was solved in 1 ml 
buffer B +DTT. 0.125ul Miccrococcal Nuclease was added into sample and 
incubated for 10 minutes at 37˚C by inverting every 3 minutes. To stop 
digestion 100 ul of 0.54 M EDTA was added into tube placed on ice.  After the 
centrifugation at 13000 rpm for 1 minute at 4 °C supernatant was removed and 
nuclear pellet was resuspended in 1 ml of 1X ChIP buffer + PIC + PMSF. 
Sample was splitted into two tubes of 500 µl and then incubated on ice for 10 
minutes. Each tube of lysates was sonicated with 8 sets of 15-second pulses 
66 
 
with Sonics Sonicator (Sonics& Materials, USA). Between pulses samples were 
incubated on wet ice for 30 seconds. To clarify, lysates were centrifuged at 
10000 rpm for 10 minutes at 4°C. Supernatant containing the cross-linked 
chromatin preparation was transferred into a new tube.  
 
3.18.2 ANALYSIS OF CHROMATIN DIGESTION AND 
CONCENTRATION 
 
25 µl of chromatin samples were mixed with 50 µl nuclease-free water, 6 µl 5 
M NaCl and 2 µl Proteinase K and incubated at 65˚C for 2 hours. DNA was 
purified as recommended in the protocol and eluted in 15 µl elution buffer. 
DNA concentration was determind with NanoDrop ND1000 spectrophotometer 
(Nanodrop technology, USA). Samples were loaded onto 1% agarose gel 
mixing with 5 µl loading dye to control DNA fragmentation. DNA should be 
digested to 1 to 5 nucleosomes (150-900 bp). 
 
3.18.3 CHROMATIN IMMUNOPRECIPITATION AND DNA 
PURIFICATION 
 
9 µg of chromatin DNA was mixed with 100 µl of 1X ChIP buffer. 10% of 
sample from each DNA+ ChIP buffer mixture was removed and kept at -20˚C 
67 
 
as input sample. H3K27me2, H3K27me3 and EZH2 antibodies were used for 
immunoprecipitations (IP) and all antibodies were used with 1:50 dilution rate. 
Primary antibodies were added into DNA + ChIP buffer mixture, samples were 
incubated for overnight at 4°C with rotation. Following day, 
immunoprecipiated samples were incubated with 30 µl of ChIP-Grade Protein 
G Agarose Beads for 2 hours at 4 °C with rotation. Washing procedures were 
followed as recommended in protocol. For reverse cross-linking of proteins, 
immunoprecipitated and input samples were mixed with 6 ul 5 M NaCl and 2 µl 
Proteinase K and incubated at 65 ˚C for 2 hours. DNA purification was 
performed using spin columns following instructions of manufacturer. 
Purification was done in 25 µl elution buffer.  
 
3.18.4 QUANTIFICATION OF IMMUNOPRECIPITATED 
DNA BY qPCR  
 
ChIP assay were analyzed with quantitative PCR using Real Q-PCR 2X Master 
mix (Ampliqon, Denmark) and results were expressed using the percent input 
method and formula was shown below:  
Percent input= (primer efficiency) ^ 
(CT input – CT IP sample) 
x percentage of input 
 
The average of “percent input” values of H3K27me2 and H3K27me3 
accumulation on adipogenic genes were calculated.  
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PCR conditions were 95˚C for 15 minutes, 95˚C for 30 seconds, 60˚C for 1 
minute, 72 ˚C for 1 minute and 30 cycles, 72 ˚C for 10 min. Each protocol was 
followed by melt curving to control purity of the amplification. Primers used 
for quanitification of immnuprecipitation were given in Table 3.1.  
 
3.19 BISULFITE SEQUENCING ANALYSIS  
 
3.19.1 BISULFITE CONVERSION  
 
DNA methylation of ERα, PPARγ and C/EBPα genes was analyzed by bisulfite 
sequencing. DNA was purified from MSCs using either DNeasy Blood&Tissue 
Kit (Qiagen) or NucleoSpin Tissue kit (Machery-Nagel, Germany) following 
the manufacturer’s instructions. Bisulifte conversion was performed using 
EpiTech Bisulfite Kit (Qiagen, USA) and 350 ng of DNA was used for each 
reaction.  
 
3.19.2 PREPARING OF DH5α COMPETENT CELLS 
 
10 l of bacteria samples from DH5 glycerol stock was streaked on Luria-
Bertani broth LB) agar plate and incubated for over-night at 37˚C. Following 
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day, single colony was picked up and incubated in 15 ml LB without selective 
antibiotic for over-night at 37˚C. Afterwards, some from 15 ml over-night 
culture was mixed with 100 ml LB in 1000 ml flask until OD600 reaches 0.2 at 
preparation mix. This mixture was incubated at 25˚C for almost 6 hours on 
shaker until OD600 reaches 0.5-0.6.  Then, bacteria culture was separated into 
two 50 ml falcons and centrifuged at 2500 g for 15 minutes at 4˚C following 
incubation on ice for 10 minutes. Supernatant was removed and cell pellet was 
resuspended in 64 ml ice-cold transformation buffer (TB) separating into two 
50 ml falcons and incubated on ice for 10 minutes. Bacteria-TB mixture was 
centrifuged at 2500 g for 15 minutes at 4˚C. Supernatant was removed and cell 
pellets were resuspended in 8 ml ice-cold TB containing 7% DMSO. Bacteria 
competent cells were aliquoted into cold 1.5 ml eppendorfs and tubes were 
immediately put into liquid nitrogen. Competent cells were stored at -80˚C. 
 
3.19.3 TA CLONING AND PLASMID DNA ISOLATION 
 
Converted DNA was used as template for bisulfite specific PCR (BSPCR) 
using HotstarTaq Polymerase (Qiagen). Bisulfite specific primers were 
designed using Methprimer software (http://www.urogene.org/methprimer/) for 
PPARγ, C/EBPα. ERα primers were designed as given in a previous study169. 
Distrubition of CpG residues in promoter regions which were examined in this 
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project were given in Figure 3.2. Primers used in BSPCR and PCR conditions 
were stated in the table 3.7 and 3.8 respectively.  
 
 
Figure 3.1 Distrubition of CpGs in promoter region Each vertical line 
represents a single CpG residue. 
 
Genes Sequences of Forward and Reverse Primers Size (bp) 
ER α forward 5'-TTAGGAATGTTGATTTTAGTGGTGT-3' 141 
  reverse 5'-TAAACAAAACACTTAACAACCCCTC-3'   
CEBP α forward 5'-TGGGTGTTTATTAGGTTTTTTTTGT-3' 167 
  reverse 5'-AACCCCCTATCCAATCCTTAAA-3'   
PPAR γ forward 5'-TTTTAGGTTTTTTTAGAAGGTGTTT-3' 368 
  reverse 5'-TCCAATTAACCCTACCCTATACTC-3'   
 
Table 3.7   List of primers used for Bisulfite Specific PCR and amplicon size  
 
 
 
Genes 
First 
Denaturation Denaturation Annealing Extension Cycle 
Final 
Extension 
CEBPα 95°C, 15 min 94°C, 60 sec 
54.5°C, 60 
sec 
72°C, 60 
sec 
30 
72°C, 10 
min 
PPARγ 95°C, 15 min 94°C, 60sec 
54.5°C, 60 
sec 
72°C, 60 
sec 
30 
72°C, 10 
min 
ERα 95°C, 15 min 94°C, 60 sec 
55.5°C, 60 
sec 
72°C, 60 
sec 
30 
72°C, 10 
min 
 
Table 3.8   Bisulfite Specific PCR conditions 
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PCR products were extracted from 1% agarose gel using QIAquick Gel 
Extraction kit (Qiagen) and purified DNA concentration was measured by 
nanodrop. Amlified and purified DNA fragment was inserted into vector with 
1:3 ratio of vector to insert. Amounts of reaction components were given in 
Table 3.9. For transformation into DH5α bacteria cells TA Cloning (pGEM -T 
Easy Vector system, Promega) was used. The Biomath calculator 
(www.promega.com/biomath) used to determine the amount of insert DNA 
needed. 10 l of ligated product was mixed with 100 l competent cells and 
incubated on ice for 20 minutes. Afterwards, the mixture were put into water-
bath at exactly 42˚C for 50 seconds and put on the ice for 2 minutes 
respectively. 950 l LB without antibiotic was added into tube and cells were 
incubated shaking at 37˚C for 1.5 hours. Tube was centrifuged at 13000 rpm for 
30 seconds and supernatant was removed. Cell pellet was solved in 100 l fresh 
LB and seeded onto LB agar plate containing amphicillin antibiotic. Plate was 
incubated for over-night at 37˚C. Following day, 5 single colonies were picked 
up and cultured in 5 ml LB with amphicillin for over-night. Plasmid DNA was 
isolated by using Plasmid Mini Kit (Qiagen, USA). 5 clones were sequenced by 
commercial services (İONTEK, Turkey and DONE Genetics, Turkey).  
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Reaction Component Volume 
2X Rapid Ligation Buffer 5 µl 
Easy Vector (50ng) 1 µl 
PCR product variable 
T4 DNA Ligase 1 µl 
Nuclease-free water   variable 
Final volume 10 µl 
               
Table 3.9 Amounts of Reaction Components for ligation 
 
3.20 STATISTICAL ANALYSIS 
 
All data from CNT experiments were analyzed with ANOVA and expressed as 
mean ± standard deviation (SD) (n=3) . Multiple comparisons of control to 
other groups were performed using Fisher's test using Minitab 15 Statistical 
Software. The statistical difference between groups in qRT-PCR and RT-PCR 
experiments were analyzed by the unpaired, Student’s t test using GraphPad 
Software and Microsoft Office Excel. The values from qRT-PCR were 
expressed as the means ± standard error (SEM) (N=3) and the values from RT-
PCR were expressed as the means ± SD (N=6). Significant difference between 
two groups was declared if p<0.05. 
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CHAPTER 4 
RESULTS 
 
In this thesis, the effect of estrogen on the maintenance and differentiation of 
MSCs was examined. First, we tested estrogen’s role during the maintenance of 
MSCs in normal culture conditions as well as using CNTs as scaffold.  In 
addition, we also tested estrogen’s genetic and epigenetic effect on the 
differentiation of MSCs into adipocyte and osteocytes. In order to accomplish 
our aim, we focused on the role of estrogen in the expression and differential 
localization of transcription factors, which are involved in adipogenesis, 
osteogenesis and chondrogenesis from MSCs. Furthermore, we examined 
histone modifications and histone modifier enzymes as well as CpG 
methylation status during differentiation.  
 
Throughout this thesis MSCs were isolated from; normal female (hereafter 
stated as female) and ovariectomized female (hereafter stated as ovex) rats. To 
investigate the role of estrogen in regulation of transcription factors involved in 
MSC differentiation in the presence of 10
-7 
M estrogen or 10
-6 
M tamoxifen in 
the cell culture media. Our experimental groups were as follows; MSCs from 
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normal female rat (hereafter stated female), estrogen treated MSCs from normal 
female rat (hereafter stated as female+est), tamoxifen treated MSCs from 
normal female rat (hereafter stated as female+tam), MSCs from ovariectomized 
rat (hereafter stated as ovex), estrogen treated MSCs from ovariectomizd 
female rat (hereafter stated as ovex+est), and tamoxifen treated MSCs from 
ovariectomized female rat (hereafter stated as ovex+tam). MSCs were cultured 
in Mesencult media for 14 days.  
 
Furthermore, at the end of the 14
th
 day of cell culture, MSCs were incubated 
with adipogenic and osteogenic induction media for differentiation. The 
differentiated cells were collected on 13
th
 day (female 13. day, female+est 13. 
day), 17
th 
day (female 17. day, female+est 17. day) and 24
th
 day (female 24. 
day, female+est 24. day) of the adipogenic and osteogenic differentiation.  
 
Finally, to investigate the effect of estrogen on the maintenance/viability of 
MSCs on CNT arrays, the cells were seeded onto multiwalled CNT (MWCNT) 
arrays in the absence and presence of estrogen. In addition, changes in the 
number and viability of attached MSCs on collagen-coated and non-coated 
CNT through passages were examined.  
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4.1 CHARACTERIZATION AND EXPERIMENTAL DESIGN 
OF CNT ARRAYS  
 
Scanning Electron Microscope (SEM) analysis was performed for 
characterization of the vertically aligned CNT arrays. Characterization was 
performed by Assist. Prof. Dr. Erman Bengü and Gökçe Küçükayan from 
Bilkent University, Department of Chemistry. SEM images of the vertically 
aligned CNT arrays revealed that CNTs were approximately 10 μm in height 
(Figure 4.1 A-B) and multi-walled with an average diameter of 10 nm. 
Experimental design of patterned CNTs was shown in Figure 4.1C. 
 
4.2 CHARACTERIZATION OF MSC 
 
MSCs were characterized both at mRNA and protein level for P0, P1 and P2 
passages. RT-PCR results demonstrated that cells from all passages express 
MSC markers, CD90, CD71 and CD29, but not hematopoietic stem cell 
markers; CD45 and CD34 (Figure 4.2A). Moreover, we confirmed this result at 
the protein level by performing western blot analysis. MSCs for all passages 
were positive for CD29, but negative for CD34 (Figure 4.2B). We also 
characterized MSCs that were used to test the effect of estrogen on their 
maintenance (Figure 4.2C). No change in the expression of the markers was 
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observed after estrogen treatment suggesting that there was no effect of 
estrogen on the characteristics of MSCs. 
 
 
Figure 4.1 Preparation of CNTs. A) 45° tilted SEM image of patterned CNT 
surfaces with the inset showing a high magnification image of the collapsed 
CNT arrays (arrow heads: collapsed and laid CNTs, arrows: CNTs that were 
shrunk to form the razor-sharp peaks) B) 45° tilted SEM image of the collagen 
coated patterned CNT surface with the inset showing the smoothing/leveling 
effect of collagen coating (dotted lines). C) Schematic representation of 
experimental design of patterned vertically alligned CNTs before cell culturing 
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Figure 4.2 Characterization of MSCs, A) Expression of MSC and HSC markers 
from P0, P1 and P2 passages of the cells at mRNA level,  B) Expression of 
MSC and HSC marker from P0, P1 and P2 passages of the cells at protein level, 
C)   Expression of MSC and HSC markers after the cells were treated with 
estrogen at P0.  
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4.3 SEEDING OF MSC ON THE CNT ARRAYS  
 
4.3.1 CELL VIABILITY OF MSCs ON NON-COATED CNTs 
IN THE PRESENCE AND ABSENCE OF ESTROGEN 
 
It was well established that estrogen promotes MSC proliferation and 
maintenance. To examine whether estrogen hormone has a positive effect on 
the cell viability of MSC seeded onto non-coated patterned CNT arrays in the 
absence and presence of estrogen, we performed MTT assay. Our results 
revealed that estrogen treatment tends to increase the viability percentage of 
MSCs on CNTs at P0 (Figure 4.3.1). 
  
 
Figure 4.3.1 Evaluation of the percent of viable MSCs isolated and seeded onto  
non-coated patterned CNT arrays by MTT assay at P0. Control group was 
79 
 
obtained from MSCs seeded on 96-well culture plates containing no CNT 
layers. 
 
 
4.3.2 CALCULATION OF THE NUMBER OF ATTACHED 
MSCs ON COLLAGEN COATED AND NON-COATED CNTs 
 
SEM analysis was performed to calculate the number of attached MSCs from 
P0, P1 and P2 passages (Figure 4.3.2 A-B). 3x10
5
 cells were seeded onto non-
coated and collagen coated patterned CNT surfaces and incubated for 3 days. 
The number of attached cells was counted and average areal density was 
calculated (Figure 4.3.2C). Our plot showed that the number of the attached 
MSCs both on collagen coated and non-coated CNT surfaces decreased through 
the passages P0, P1 and P2. The decrease in the number was significant at P1 
and P2 compared to P0, however no significant change was observed between 
P1 and P2.  
 
In addition, our result clearly showed that the number of the MSCs was 
significantly higher on non-coated CNT arrays compared to collagen coated 
CNT arrays at P0, but not at P1 and P2 groups. These data suggest that early 
passages of MSCs have higher attachment potential on CNT array. Moreover 
collagen coating of CNT surfaces have a negative effect on attachment of cells 
from P0, whereas no change was observed at P1 and P2.   
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4.3.3 CELL VIABILITY OF PASSAGED MSCs ON 
COLLAGEN-COATED AND NON-COATED CNTs 
 
To understand whether the patterned CNT arrays have any cytotoxic effect on 
cell viabilty, we examined the effect of collagen coated and non-coated CNTs 
on MSCs from subsequent three passages performing MTT assay. MSCs which 
were cultured on cell culture plate containg no CTN layers were used as control 
group. Our results clearly demonstrated that MSCs viability was significantly 
higher at P0 compared to P1, P2 and control group (Figure 4.3.3). 
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Figure 4.3.2 Scanning Electron Microscope images of MSCs at P0 after 
seeding and culturing for 3 days on the a) non-coated patterned CNTs and b) 
collagen coated patterned CNTs , c)  Average area density of MSCs on non-
coated (represented by -) and collagen coated (represented by +) patterned CNT 
arrays at P0, P1 and P2. ANOVA was significant at p<0.001. Multiple 
comparisons of control to other groups were performed using Fisher's test 
(Minitab 15 Statistical Software). * indicates p<0.05 and ** indicates p<0.001, 
Mean ± Standard Deviation 
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Therefore, we can state that patterned CNT arrays have no cytotoxic effect on 
viability of MSCs from P0.  Also, we suggest that either collagen coated or 
non-coated patterned CNT arrays may provide a suitable environment for 
MSCs to survive. 
 
 
Figure 4.3.3 The percent of viable MSCs on non-coated patterned (empty bars) 
and collagen coated patterned CNT arrays (solid bars) at P0, P1 and P2 by MTT 
assay. Control group was obtained from cells seeded on 96-well culture plates 
without CNT arrays. ANOVA was significant at p = 0.041 and p<0.001 for 
non-coated and collagen coated CNT arrays, respectively. Multiple 
comparisons of control to other groups were performed using Fisher's test 
(Minitab 15 Statistical Software). * indicates p<0.05, Mean ± Standard 
Deviation 
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4.4 EXPRESSION OF TRANSCRIPTION FACTORS 
INVOLVED IN ADIPOGENIC, OSTEOGENIC AND 
CHONDROGENIC DIFFERENTIATION IN MSCs 
 
To investigate the effect of estrogen treatment in the genetic regulation of 
transcription factors, which are required for adipogenic, osteogenic and 
chondrogenic differentiation of MSC, we first examined their mRNA levels in 
MSCs obtained from normal female and ovex rats and cultured in the absence 
and presence of estrogen. By performing qRT-PCR, we evaluated the effect of 
estrogen on adipogenic transcription factors; PPARγ, C/EBPα, FABP4, 
Adipsin, osteogenic transcription factors; RUNX2, ETS1 and chondrogenic 
transcription factors; SOX9, ATF3 and MEF2C. Cyclophilin was used as a 
housekeeping gene and expression results of transcription factors were 
normalized according to Cyclophilin expression. Female samples were used as 
calibrator.   
 
We found a decrease in the expression level of adipogenic genes in both female 
and ovex animals when MSCs were incubated in the presence of estrogen. This 
finding suggested that estrogen might have an inhibitory effect on the 
expression of adipogenic transcription factors (Figure 4.4 A-D). 
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It was well established that estrogen has a stimulatory effect on bone and 
cartilage formation. In this study, we observed a significant increase in mRNA 
level of RUNX2, osteogenic transcription factor, upon estrogen treatment in 
MSCs isolated from both female and ovex rats as expected (Figure 4.4E). On 
the contrary, we demonstrated that estrogen has an opposite effect on the 
transcriptional regulation of another osteogenic gene, ETS1. Estrogen treatment 
caused a significant reduction in ETS1 gene expression both in female and ovex 
animals (Figure 4.4F). 
 
Furthermore, estrogen treatment enhanced expression rates of chondrogenic 
transcription factors in female animals. But we could not detect an expected and 
consisted expression pattern in chondrogenic genes in ovex samples (Figure 4.4 
G-I). Estrogen treatment resulted a significant decrease in SOX9 and ATF3 
expression, whereas MEF2C level increased as expected upon estrogen 
treatment in ovex samples. Fold changes and P values of each gene for all 
groups were provided in Table 4.1. 
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Figure 4.4 Effect of estrogen on the expression profile of the (A-D) adipogenic 
(E, F) osteogenic and (G-I) chondrogenic transcription factors in MSCs by 
qRT-PCR at P0. Relative expression to cyclophillin was calculated. N=6, * 
indicates p<0.05, ** indicates p<0.0001, Mean ± Standard Deviation 
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GENES 
FEMALE 
+EST vs 
FEMALE P VALUE 
OVEX vs 
FEMALE P VALUE 
OVEX+EST 
vs OVEX P VALUE 
PPAR 0.95 0.6772 1.67 <0.0001 0.72 <0.0001 
C/EBP 0.92 0.832 1.54 0.172 0.71 0.0001 
FABP4 0.517 0.0001 1.497 <0.0001 0.369 <0.0001 
ADIPSIN 0.25 <0.0001 1.92 <0.0001 0.729 <0.0001 
RUNX2 1.99 <0.0001 0.855 0.0022 1.22 0.0002 
ETS1 0.66 0.0007 4.56 <0.0001 0.288 <0.0001 
MEF2C 1.6 <0.0001 8.9 <0.0001 1.434 <0.0001 
SOX9 1.25 <0.0001 5.064 <0.0001 0.29 <0.0001 
ATF3 1.098 0.25 0.8169 0.0466 0.302 <0.0001 
 
Table 4.1 Fold changes and P values were calculated using Unpaired Student t 
test for each gene. Estrogen treated MSCs were compared to untreated MSCs. 
Ovex MSCs were compared to female MSCs.   
 
 
 
4.5 EXPRESSION OF ADIPOGENIC AND OSTEOGENIC 
TRANSCRIPTION FACTORS IN DIFFERENTIATED MSC 
 
We investigated changes in the expression level of the adipogenic transcription 
factors during differentiation of MSCs to adipocytes at different time points.  At 
first, cells were stained with Oil Red O on the 13
th
 and 24
th
 day of adipogenic 
induction to check differentiation (Figure 4.5A). As a negative control, the cells 
were incubated in DMEM with no differentiaton induction factors for 24 days 
in the presence and absence of estrogen. The non-induced cells were also 
stained with Oil Red O on the 13
th
 and 24
th
 days of differentiation(Figure 4.5B). 
Lipid vacuole formation increased at the end of the 24
th 
days of induction. No 
droplets were seen at negative controls.  
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Figure 4.5 Detection of adipogenic differentiation of MSCs isolated from 
female rats and cultured in the absence and presence of estrogen. A) Cells were 
stained with Oil Red O on the 13
th
 day and 24
th
 day of the induction. B) Cells 
were incubated only in DMEM in the absence/presence of estrogen and stained 
with Oil Red O on the 13
th
 day and 24
th
 day of the culture and used as negative 
control. 
 
To see whether estrogen treatment alters the mRNA expression of adipogenic 
transcription factors during differentiation, we performed RT-PCR for PPARγ, 
FABP4 and C/EBPα genes. MSCs which were isolated from normal female rats 
and cultured in the absence and presence of estrogen, were collected on the 13
th 
day, 17
th
 day and 24
th
 day of the adipogenic differentiation. Our RT-PCR 
results revealed that estrogen has an opposite effect on the expression of 
PPARγ, FABP4 and C/EBPα genes in adipocytes compared to that of 
MSCs.We found that expression of the adipogenic transcription factors tends to 
increase after estrogen treatment in adipocytes differentiated from MSCs both 
on the 13
th
 day and 24
th
 day of the differentiation (Figure 4.6) 
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Figure 4.6 Effect of estrogen on the expression profile of the adipogenic 
transcription factors in adipocytes differentiated from MSCs by RT-PCR. The 
cells were isolated at the end of the 13
th
, 17
th
 and 24
th
 day of adipogenic 
differentiation. Semi quantitative analysis was done relative to β-actin 
expression. N=3, Mean ± Standart Error 
 
 
 
According to our qRT-PCR results, estrogen treatment resulted a significant 
increase of RUNX2 osteogenic transcription factor in MSCs. To see how 
estrogen treatment influences the mRNA level of RUNX2 during osteogenic 
differentiation, MSCs were induced in osteogenic induction medium for 24 
days. The cells were stained with alizarin red on the 13
th
 and 24
th
 days of 
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induction to determine osteogenic differentiation (Figure 4.7A). As negative 
control, cells were incubated in DMEM without differentiaton induction factors 
for 24 days in the presence and absence of estrogen. The non-induced cells 
were also stained with Alizarin Red on the 13
th
 and 24
th
 days of differentiation 
(Figure 4.7B). Calcium deposits were detected at the end of the 13
th
 and 24
th
 
days of induction. No staining was seen at negative control samples. 
 
 
Figure 4.7 Detection of osteogenic differentiation of MSCs isolated from 
female rats and cultured in the absence and presence of estrogen. A) MSCs 
were stained with Alizarin Red on the 13
th
 day and 24
th
 day of the 
differentiation culture. B) As negative control, the cells were incubated only in 
DMEM in the absence/presence of estrogen and stained with Alizarin Red on 
the 13
th
 day and 24
th
 day of the differentiation culture 
 
 
The cells were collected on the 13
th
 day, 17
th
 day and 24
th
 day of the osteogenic 
differentiation to investigate the alteration in the expression of RUNX2 gene 
during differentiation. It was observed that expression of the RUNX2 gene 
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tends to increase upon estrogen treatment in osteocytes differentiated from 
MSCs both on the 17
th
 day and 24
th
 day of osteogenic induction (Figure 4.8).  
 
 
Figure 4.8 Effect of estrogen on the expression profile of RUNX2 in osteocytes 
differentiated from MSCs by RT-PCR. Cells were isolated at the 13
th
, 17
th
 and 
24
th
 day of osteogenic differentiation.Semi quantitative analysis was done 
relative to β actin expression. N=3, Mean ± Standart Error 
 
 
4.6 TRANSCRIPTION FACTOR LOCALIZATION  
 
Our qRT-PCR and RT-PCR results revealed that the presence of estrogen 
caused a change in the expression of transcription factors involved in MSC 
differentiation. To detect whether estrogen deficiency influences transcription 
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factor localization in MSCs, we performed western blotting and 
immunofluorescence labeling.  
 
We first controlled whether cytoplasmic and nuclear fraction of cells can be 
separated properly. For this purpose, we examined Calnexin expression, which 
localizes in cytoplasm, and Cyclin E1expression, which localizes nucleus, in 
two different fractions (Figure 4.9.) 
 
 
 
Figure 4.9 Confirmation of procedure performed to seperate nuclear and 
cytoplasmic fraction in MSCs isolated from normal female animal by western 
blotting at P0 using Calnexin and cylin E1 antibodies which localize cytoplasm 
and nucleus, respectively. 
 
 
Immunofluorescence results revealed that estrogen deficiency cause a dramatic 
alteration in the subcellular localization of two transcription factors; PPARγ and 
ETS1. PPARγ localized in cytoplasm and especially in endoplasmic reticulum 
in female, while it was in nucleus in ovex (Figure 4.10). Thus, the presence or 
absence of estrogen seems to have effect on the succellular localization of 
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PPARγ. On the other hand, estrogen treatment did not interfere with the 
accumulation pattern of PPARγ protein in MSCs isolated from either female or 
ovex as shown by western blot (Figure 4.11). 
 
 
Figure 4.10 Subcellular localization of PPARγ protein in MSCs isolated from 
female and ovex rat and cultured in the absence and presence of estrogen by 
immunofluorescence staining at P0 (Magnification 20X). 
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Figure 4.11 Subcellular localization of PPARγ protein in MSCs isolated from 
female and ovex rat and cultured in the absence and presence of estrogen by 
western blotting at P0. 
 
 
We also tested the effect of estrogen in the subcelluar localization of osteogenic 
transcription factor ETS1both in MSCs isolated from female and ovex animals. 
Our results showed that ETS1 protein was mainly in cytoplasm in female, 
whereas it localized in both cytoplasm and nucleus in ovex by 
immunofluorescein (Figure 4.12) and western blotting (Figure 4.13). 
 
95 
 
 
Figure 4.12 Subcellular localization of ETS1 protein in MSCs isolated from 
female and ovex rat and cultured in the absence and presence of estrogen by 
immunofluorescence staining at P0 (Magnification 20X). 
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Figure 4.13 Subcellular localization of ETS1 protein in MSCs isolated from 
female and ovex rat and cultured in the absence and presence of estrogen by 
western blotting at P0 (Magnification 20X). 
 
 
 
4.7 EFFECT OF ESTROGEN ON THE EXPRESSION OF 
HISTONE MODIFICATION PROTEINS AND ENZYMES  
IN MSCs  
 
Previously, by our group it was demonstrated that estrogen treatment protects 
MSCs from apoptosis. It is possible that estrogen can regulate the expression of 
target genes changing the modifications on the histone protein. To test this 
possibility, we evaluated expression level of histone modifications; H3K27me2, 
H3K27me3, H3K9me2, H3K9me3 and H3K36me2 (Figure 4.14) and modifier 
enzymes; H3K27 methyltransferase EZH2, H3K9 demetyhlase LSD1 and 
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H4K9 methyltransferase SET 7/9 (Figure 4.15) upon estrogen treatment. We 
performed western blotting using acid extracted histone proteins and found that 
H3K27me2, H3K27me3 and H3K36me2 protein levels tend to decrease after 
estrogen treatment both in female and ovex animals (Figure 4.14A, 4.14B, 
4.14E). For H3K9Me2 and H3K9Me3, estrogen tends to have a positive effect 
in MSCs isolated from ovex but not from female animals (Figure 4.14C, 
4.14D). 
 
Our results also showed that the level of histone modifier enzymes; EZH2, 
LSD1 and SET 7/9 were also affected from estrogen. However fluctuations in 
the level of enzymes were not consistent. Additionally, any correlation was not 
observed between protein level of modifed histones; H3K27me2/me3, 
H3K9me2/me3 and modifier enzymes; EZH2 and LSD1. (Figure 4.15A, 
4.15B). On the other hand, SET 7/9 showed a consistent expression pattern 
between treated and untreated samples. It was observed that SET 7/9 expression 
tends to decrease upon estrogen treament both in ovex and normal female 
MSCs (Figure 4.15C).    
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Figure 4.14 Evaluation of total protein level of histone modification proteins in 
MSCs by western blotting at P0. H3 was used as loading control and protein 
levels were normalized according to H3 expression. 
 
 
 
 
99 
 
 
Figure 4.15 Evaluation of total protein level of histone modifier enzymes 
proteins in MSCs by western blotting at P0. Actin and Calnexin was used as 
loading control and protein expression results were normalized according to 
Actin and Calnexin expression.  
 
 
 
4.8 ChIP ASSAY 
 
4.8.1 EZH2, H3K27me2 AND H3K27me3 BINDING STATUS 
ON ADIPOGENIC GENES  
 
Identification of binding status of histone modifications on key adipogenic 
transcription factors is critical to understand epigenetic regulation mechanism 
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of estrogen. qRT-PCR results showed that estrogen has an inbitory effect on 
adipogenic transcription factors examined in this thesis. In order to test  
whether estrogen treatment changes the accumulation of inactive histone marks; 
H3K27me2, H3K27me3 and EZH2 enzyme on adipogenic genes, we performed 
ChIP analysis in estrogen treated, tamoxifen treated and untreated MSCs 
obtained from both female and ovex rats.  
 
After the chromatin digestion, 25 l of digested chromatin samples were mixed 
with Proteinase K and incubated at 65 ˚C for 2 hours for reverse-crosslinking. 
DNA was purified as recommended in protocol. DNA concentration was 
determined and samples were loaded onto agarose gel to check DNA 
fragmentation. We clearly observed fragments, which 150 bp in length, in all 
samples (Figure 4.16). 
 
 
Figure 4.16 Confirmation of the digestion of chromatin samples in MSCs  at P0 
from A) Female (i), Female+est (ii), B) Ovex (i),  Ovex+est (ii), C) 
Female+tam (i), Ovex+tam (ii), by agarose gel electrophoresis . Arrow 
indicates 150 bp. 
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After estrogen treatment, the occupancy of inactive marks; H3K27me2 and 
H3K27me3 tend to increase on the PPARγ, C/EBPα, FABP4 and Adipsin 
promoter regions in MSCs isolated from both female (Figure 4.17A) and ovex 
(Figure 4.17B). Moreover, when we treated MSCs with tamoxifen, which is an 
estrogen receptor antagonist, H3K27me2 and H3K27me3 accumulation on 
these genes promoters tend to reduce. EZH2 level on the adipogenic genes also 
tend to increase following estrogen treatment, especially in female rats (Figure 
4.18A-D). 
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Figure 4.17 Histone modifications at the adipogenic genes: ChIP analysis of 
H3K27me2 and H3K27me3 in MSCs from normal (A) and ovariectomized (B) 
female animals and cultured in the absence and presence of either estrogen or 
tamoxifen. Quantitative PCR was performed on immunoprecipiated DNA 
fragments using primers for the PPARγ, C/EBPα, FABP4 and Adipsin. The 
average of “percent input” values of H3K27me2 and H3K27me3 accumulation 
on adipogenic genes were calculated.  
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Figure 4.18 EZH2 occupancy at the adipogenic genes: ChIP analysis of EZH2 
in MSCs from normal and ovariectomized female animals and cultured in the 
absence and presence of either estrogen or tamoxifen. Quantitative PCR was 
performed on immunoprecipiated DNA fragments using primers for the 
PPARγ, C/EBPα, FABP4 and Adipsin.  
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4.8.2 H3K27me2 AND H3K27me3 BINDING STATUS ON 
RUNX2 GENE  
 
According to qRT-PCR results, estrogen hormone acts as a transcriptional 
activator of RUNX2 gene. To understand whether RUNX2 gene is regulated by 
estrogen through methylation of H3K27, we investigated the accumulation 
status of this type of histone modifications on RUNX2 gene promoter. 
Interestingly, after the estrogen treatment, H3K27me2 and H3K27me3 (Figure 
4.19A-B) occupancy tend to increase on the RUNX2 promoter region.  
 
 
 
Figure 4.19 Histone modifications at RUNX2 gene: ChIP analysis of 
H3K27me2 and H3K27me3 in MSCs isolated from A) female and B) ovex 
animals and cultured in the absence and presence of either estrogen or 
tamoxifen. Q-PCR was performed on immunoprecipiated DNA fragments using 
primers for RUNX2. The average of “percent input” values of H3K27me2 and 
H3K27me3 accumulation on adipogenic genes were calculated.  
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Consistent with this data, when MSCs were treated with an estrogen receptor 
antagonist, tamoxifen, H3K27me2 and H3K27me3 levels at RUNX2 promoters 
tend to reduce. 
 
 
4.8.3 ERα BINDING STATUS ON ADIPOGENIC AND 
OSTEOGENIC GENES  
 
As we have shown, estrogen treatment resulted in an increase of H3K27me2 
and H3K27me3 occupancies on PPARγ, C/EBPα, FABP4, Adipsin and 
RUNX2 promoter regions. Estrogen receptors convey the regulatory signal of 
estrogen interacting with coactivators, corepressors, HATs and histone 
deacetylases HDACs to control the transcription of target genes. We have 
performed ChIP assay to understand how binding of ER changes on 
transcription factors upon estrogen treatment. We demonstrated that 
accumulation of ER tend to increase on promoter regions after estrogen 
treatment in female (Figure 4.20).  
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Figure 4.20 ERα occupancy at the adipogenic genes and RUNX2 gene: ChIP 
analysis of ERα in MSCs from normal female animals and cultured in the 
absence and presence of either estrogen.Quantitative PCR was performed on 
immunoprecipiated DNA fragments using primers for the PPARγ, C/EBPα, 
FABP4, Adipsin and RUNX2.  
 
 
 
 
4.9 CpG METHYLATION STATUS OF ADIPOGENIC GENE 
PROMOTERS 
 
In addition, we examined the DNA metyhlation status of adipogenic genes. For 
this purpose, CpG methylation analysis of ERα and two major transcription 
factors PPARγ, and C/EBPα promoters was performed in polyclonal cultures of 
MSCs. We determined the level of CpG methylation at each gene by taking the 
average percentage of CpG methylation from three colonies to create a CpG 
107 
 
methylation pattern table for ERα PPARγ, and C/EBPα genes. Bisulfite 
sequencing analyses revealed DNA hypermethylation in C/EBPα and PPARγ 
promoters after estrogen treatment in MSCs from female animals as expected 
(Figure 4.21A). On the other hand, in ovex rats estrogen treatment caused a 
decrease in percentage of DNA methylation (Figure 4.21B). Furthermore, it 
was also observed that ERα shows an opposite CpG methylation pattern 
compared to C/EBPα and PPARγ both in female and ovex animals. Mosaicism 
in the methylation status of CpGs between colonies was also seen on promoters 
of adipogenic genes and ERα. Methylation variation between clones was also 
demonstrated in Figure 4.22  
 
 
 
Figure 4.21 Determination of the level of CpG methylations at PPARγ, 
C/EBPα, and ERα promoters in MSCs by bisulfite sequencing analysis at P0. 
Bisulfite converted DNA was amplified with bisulfite specific primers for 
PPARγ, C/EBPα and ERα. Average percentage of CpG methylation from three 
colonies in female and ovex animals was taken. 
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Figure 4.22 Bisulfite analysis of ERα, PPARγ and C/EBPα in 3 MSC clones 
from one normal and ovariectomized rat.  Methylated CpG is indicated by ● at 
each locus for each clone. X indicates the CpG residues which could not be 
sequenced.  
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CHAPTER 5 
DISCUSSION 
 
Identification and characterization of stem cells provide opportunities to 
develop treatment options for several diseases. Because of this reason, the 
improvement in isolation, identification and therapeutic applications of stem 
cells has generated great excitement. The ethical problems related the use of 
ESC and the issues associated with effective using of iPS cells such as possible 
viral integration site increased the therapeutical value of ASCs. Among the 
other ASCs, MSCs have a distinguished place due to their unique features. First 
of all MSCs can be isolated from different parts of the body like bone marrow, 
adipose tissue, liver, dental pulp, umblical cord and blood. These cells have 
immune-privileged feature which permits the allogeneic transplantation and 
have homing ability which enables the migration to injured tissue easily. Due to 
these reasons, MSCs are suitable cell source for stem-cell based applications 
and tissue engineering.  
 
In last decade, there have been numerous advances in tissue engineering to 
repair and replace injured organ and tissue by using stem cells. For this 
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purpose, many attempts have been applied to generate suitable scaffold 
material. Carbon nanotubes have become attractive scaffold materials due to 
their remarkable properties chemical stability, nano-scale size and electrical 
comductivity. On the other hand maintenance of attachment, growth, 
proliferation differentiaton of the cells on the scaffold surfaces is critical point 
in biomaterial applications. Estrogen hormone plays a key role in regulation of 
proliferation, differentiation and maintenance of cells and it has been shown by 
us and others that estrogen has also very important regulatory functions on 
MSCs 17-β estradiol (E2) enhances effectively MSC proliferation and up-
regulates HTERT and telomerase activity preventing telomere shortening in 
MSCs
154,170,171
. In previous study, our group reported the inhibitory effect of 
estrogen on apoptosis through modulating the expression of Bcl-2 family 
genes
79
. Therefore, in this thesis we aimed to investigate effects of estrogen on 
MSC viability both on normal cell culture conditions and on CNT surfaces and 
investigated estrogen’s genetic and epigenetic effects on MSC.  
 
We first tested whether CNT surfaces have any effect on the characteristics of 
MSCs. Our results showed that MSCs were positive for the expression of MSC 
markers (CD90, CD71 and CD29) but negative for hematopoietic stem cell 
markers (CD45 and CD34) for all passages (Figure 4.2). These data suggest that 
exposure to CNT does not affect the features of MSCs. In order to understand 
the effect of estrogen on the viability and maintenance of MSCs on CNT 
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surfaces, the cells were incubated in the presence and absence of estrogen for 
14 days. Moreover, the effect of non-coated and collagen coated CNTs on three 
passages (P0-P3) were also investigated. The passaged cells were incubated on 
non-coated and collagen coated CNT surfaces.  Our plot revealed that the 
number of the MSCs decreased through the passage of the cells. The decrease 
was statistically significant when the number of the cells were compared 
between P0 and P1 and P2 (Figure 4.3.2c). Thus, these data suggest that very 
early passages of MSCs should be used for seeding purposes. The number of 
the cells both on coated and non-coated patterned CNTs continued to decrease 
at P2 compared to P1 but we did not observe a statistical significance between 
them. Interestingly, the number of the MSCs was significantly higher when 
they were cultured on non-coated compared to that of collagen coated CNT 
arrays at P0 but not at P1 and P2. Especially in bone tissue engineering, the 
scaffold material is the key component. An ideal scaffold should support 
growth of bone tissue having high porosity and unique physical properties
175
. It 
was demonstrated that, single-walled carbon nanotubes (SWNTs) are potential 
promising scaffold material for bone tissue engineering. They have also 
injectable and cytocompatible features and can mechanically improve the bone 
tissue formation
65,175,176
.  Furthermore, a few investigations were done focusing 
on potential applications of SWNTs in drug delivery and cancer therapy
177
. Due 
to the smilar sizes with protein fibers that are used in cell growth media, CNTs 
can be considered as an alternative 3D collagen scaffold surface. Rat primary 
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osteoblasts were implanted on the CNT-coated sponge and succesfull bone 
formation was detected
78
. CNTs were also used as carrier materials for bone 
morphogenetic protein
178
. On the other hand, in some studies the 
biocompatibility and cytotoxicity of CNTs were discussed. It was demonstrated 
that powdered multi-walled carbon nanotubes (MWCNT) have a cytotoxic 
effect on mouse embryonic stem cells inducing DNA damage
179
. On the 
contrary, it was also shown that the patterned surface of CNTs support adhesion 
and growth of fibroblasts without any toxic effects promoting firmly attachment 
of cells to the surface
180,181
. Since there are concerns about the cytotoxic effect 
of CNT, we examined the viability of MSCs using MTT assay for estrogen 
treated and untreated samples. Contrary to previous concerns about the 
deleterious effect of CNT array on cells, we did not detect a toxic effect on the 
viability of MSCs (Figure 4.3.3). Furthermore, estrogen treatment enhanced the 
viability of cells comparing to untreated cells (Figure 4.3.1). As a conclusion 
we suggested that scaffolds comprised of CNTs can be used for seeding MSCs 
due to their non toxic properties and estrogen treatment enhances the 
maintenance of MSCs on CNT scaffold arrays. 
 
Our results also showed that MSCs from early passages (P0) not only had the 
highest capacity of viability both on non-coated and collagen coated patterned 
CNT surfaces, but also higher than the control groups, whereas this level 
increased through the passages. Our MTT result was also parallel to the result 
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of calculation of the number of attached MSCs on collagen coated and non-
coated CNTs. The cells were calculated under SEM and it was detected that 
number of attached cells significantly decreases through the passages. This 
result can be explained by the aging of MSCs
8
. According to these results we 
concluded that CNT has no cytotoxic effect on MSCs at P0 both on collagen 
coated and non-coated surfaces. On the other hand, the negative effect of CNTs 
on the metabolic activity of MSCs can be seen on later passages. Thus, our data 
demonstrated that either non-coated or collagen coated patterned CNT arrays 
provide an ideal native environment for cells from early passages to maintanece 
the differentiation potential. Overall, this study demonstrated that patterned 
CNT arrays can serve as a permissive scaffold for MSC growth and adhesion. 
CNT has no adverse effects on cell biocompatibility, proliferation and they are 
not biodegradable and as such that they can be used as scaffolds where long-
term substrates are needed for tissue engineering such as in regeneration after 
spinal cord or brain injury. 
 
After observing the similar response of estrogen on the maintenance and 
proliferation of MSCs when cultured either on CNTs or normal culture 
conditions, we focused on the role of estrogen on genetic and epigenetic 
regulation of MSCs by using normal culrure conditions.  For this purpose, first, 
we investigated the effect of estrogen in regulation of transcription factors 
involved in MSC differentiation.  
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We examined the mRNA expression levels of transcription factors which are 
necessary for MSC differentiation and demonstrated that estrogen treatment 
causes decrease in expression level of four major adipogenic transcription 
factors; PPARγ, C/EBPα, FABP4 and Adipsin (Figure 4.4A-D) both in normal 
female and ovex animals. Significant increase in mRNA levels of osteogenic 
transcription factor RUNX2, upon estrogen treatment was also shown (Figure 
4.4E). In previous studies it was demonstrated that estrogen represses 
adipogenesis through inhibiting expression of early and late adipogenic 
differentiation markers while promoting osteogenesis in MSCs
145,146,182
. We 
showed this inhibitory and stimulatory effect of estrogen hormone on 
adipogenic and osteogenic transcription factors respectively, especially in ovex 
samples which were treated with 10 
-7
 M estrogen in cell culture. Estrogen 
deficiency is considered as major cause of osteoporosis, osteoarthritis and 
obesity in postmenopausal women
162-166,
 
183
. It was well established that there is 
a balance between adipogenesis, osteogenesis and chondrogenesis. Estrogen has 
a stimulator effect on bone and cartilage formation while inbiting adipogenic 
differentiaton
183
. The inverse relationship between adipogenesis, osteogenesis 
and chondrogenesis requires to be further elucidated. Our results suggested that 
estrogen inhibits adipogenesis decreasing expression of PPARγ, C/EBPα, 
FABP4 and Adipsin transcription factors, whereas it stimulates osteogenesis 
increasing RUNX2 expression in MSCs isolated from both female and ovex 
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rats. This result would attribute the key role to estrogen in MSC differentiation 
and can improve the usage of MSCs in treatment of obesity, osteoporosis and 
estrogen deficiency related diseases.  
 
ETS1 plays pivotal role in osteogenesis interacting with RUNX2 to control 
osteogenic differentiation especially in preosteoblasts. We have observed that 
estrogen has an opposite effect on the expression of ETS1 (Figure 4.4F). 
Interestingly, the highest ETS1 level was demonstrated in ovex animals. 
Therefore we proposed that estrogen deficiency may inhibit ETS1 expression in 
MSCs and osteogenesis may be controlled through the regulation of RUNX2 
gene by estrogen addition.  
 
On the other hand, estrogen treatment caused reduced expression level of 
chondrogenic transcription factors; MEF2C, SOX9 and ATF3 in female 
animals as expected. But we could not observe similar and consisted expression 
pattern in ovex samples (Figure 4.4G-I). In a previos study it was reported that 
estrodial treament may inhibit the condrogenesis in a dose dependent manner in 
spite of the fact that estrogen is crucial for normal longutinal growth and its 
deficiency causes osteoarthiritis in postmenopausal women
161
. We suggest that 
the differences in response pattern of chondrogenic genes may be the result of 
the concentration of estrogen used in treatment of MSCs in ovex rats. Another 
possibility could be that estrogen treatment alone is not responsible in the 
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regulation of chondrogenesis in MSCs due to the absence of the other 
regulatory factors or pathways that are involved in this process. 
 
Interestingly, significant reduction after estrogen treatment both in female and 
ovex animals was observed in the expression of FABP4 and Adipsin genes. 
Adipocyte differentiation is regulated by a network including numerous of 
transcription factors. These transcription factors are required for establisment of 
the mature fat cell phenotype
182,
 
183,
 
184. PPARγ and C/EBPα are at the center of 
this network and responsible for the regulation of adipocyte specific genes such 
as FABP4 and Adipsin
185-187
.  In the light of this knowledge and according our 
results, we proposed that since the FABP4 and Adipsin are downstream 
adipogenic genes, the significant change in expression level is only observed in 
these genes.  
 
In contrast to known stimulatory effect of estrogen, estrogen receptor, liganded 
ERα also represses the gene expression recruiting corepressors/histone 
deactylases (HDAC) containing complexes enables establishment of 
hypermethylation on specific CpG loci
153,154,190
. Stossi reported that histone 
acetyltransferase p300 binds to both E2 (estradiol)-repressed and E2-stimulated 
genes with other co-activator SRC-3. This accumulation causes transient gene 
activation. After formation of early transient complex of p300:SRC3 with 
pioneer transcription factors, histone deacetylas CtBP1, is recruited with p300 
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on E2-repressd genes. We demonstrated that estrogen has an opposite effect on 
adipogenic genes in adipocytes derived from MSCs in normal female (Figure 
4.6). While estrogen treatment causing decreases in expression of PPARγ, 
C/EBPα, FABP4 and Adipsin, it stimulates adipogenic gene expression in 
adipose cells differentiated from MSCs. Our results suggested that estrogen can 
show either its stimulator or repressor function on the same genes depending on 
the cell type. In addition, estrogen maintains to stimulate expression of RUNX2 
gene in osteocytes differentiated from MSCs in normal female (Figure 4.8).  
 
Furthermore, among the other transcription factors, we detected the localization 
change only in PPARγ (Figure 4.10, Figure 4.11) and ETS1 (Figure 4.12, 
Figure 4.13) proteins upon estrogen deficiency. PPARγ localization shifted 
from endoplamic reticulum to nucleus in response to estrogen deficiency. ETS1 
protein was mainly in cytoplasm in female whereas it localized both in 
cytoplasm and nucleus in ovex animals. These results were consistent with our 
mRNA expression level data.  
 
To support our genetic results, we aimed to examine the epigenetic regulation 
mechanisms which control transcription factors in MSCs with emphasis on 
adipogenic and osteogenic genes. Our western blotting results revealed a higher 
protein level of H3K27me2, H3K27me3 and H3K36me2 in untreated MSCs 
obtained both normal and ovex animals comparing to estrogen treated samples 
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(Figure 4.14). With this result we could also confirm a previous study in which 
it was reported that H3K27me3 and H3K9me3 are significantly higher in MSCs 
from ovex mice comparing to sham-operated mice
146 
. 
 
The opposite relationship between osteogenesis and chondrogenesis was also 
tried to explain at epigenetic level in a previous study by Ye et.al in 2012
146
. In 
this study it was shown that JMJD2B and JMJD3B enzymes are involved in 
osteogenic differentiation of MSCs by removing H3K9me3 and H3K27me3. 
Upon osteogenic induction, overexperssion of these demethylases enhances the 
expression of alkaline phospahatase (ALP), which is an osteoblast 
differentiation marker. On the other hand, depletion of JMJD2B and JMJD3B 
causes a significant increase in adipogenic differentiaton in MSCs.  
 
On the other hand, histone modifier enzymes; EZH2, LSD1 and SET 7/9 were 
also affected by estrogen, but there is no correlation between the global protein 
expression rates of modifier enzymes and modified histone proteins after 
estrogen treatment (Figure 4.15).   Although the inhibitory effect of estrogen on 
total H3K27me2 and H3K27me3 protein levels in MSCs, enhanced occupancy 
of H3K27me2 and H3K27me3 on the promoters of adipogenic genes; PPARγ, 
C/EBPα, FABP4 and Adipsin, upon estrogen treatment was demonstrated by 
ChIP analysis. Furthermore, the addition of tamoxifen, which is an estrogen 
receptor antagonist, caused a decrease in the accumulation of H3K27me2 and 
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H3K27me3 (Figure 4.17). In conclusion we could demonstrate that however 
estrogen treatment reduces total protein level of H3K27me2, H3K27me3, it 
causes the enhanced accumulation of of inactive marks; H3K27me2 and 
H3K27me3, on adipogenic gene promoters in order to repress transcription.  
 
 In addition, we demonstrated that estrogen treatment also regulate the 
occupancy of methylated H3K27 proteins on RUNX2 gene (Figure 4.19). The 
reduced EZH2 phosphorylation increases H3K27 trimethylation and causes 
repression of RUNX2 and osteopontin genes, which are osteogenic markers
191
. 
As contradiction to this finding and in contrast to our qRT-PCR results, 
H3K27me2 and H3K27me3 binding is also enhanced upon estrogen treatment 
on RUNX2 promoter as well as on PPARγ, C/EBPα, FABP4 and Adipsin 
promoters. It was known that genes which have bivalanet promoters are 
regulated by a combination of histone marks
191,193,194
. These domains consist of 
regions for both inactive and active histone modifications such as H3K27 and 
H3K4. From this result we concluded that RUNX2 gene may be regulated by 
another active histone marks such as H3K4 or H3K36, which are stimulated to 
bind to RUNX2 upon estrogen induction.  
 
Furthermore, the important role of H3K27 methyltransferase EZH2 in the 
inhibition of MSCs differentiation was reported. We showed that estrogen 
induced the accumulation of EZH2 on adipogenic genes, especially in female 
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animals (Figure 4.18). Our results suggested that estrogen regulates the 
expression of key adipogenic transcription factors altering the binding of 
H3K27me2, H3K27me3 and their methyltransferase enzyme EZH2. By this 
mechanism, estrogen influences the adipogenesis commitment of MSCs.  
 
Another important finding is the ehnanced binding of ERα to PPARγ, C/EBPα, 
FABP4, Adipsin and RUNX2 after estrogen treatment in normal female 
animals (Figure 4.20). As mentioned, ERα have both stimulator and repressor 
function in the regulation of expression of target genes. ERα recruits 
corepressors/HDAC and costimulators/HAC enzyme complexes
150-154
. On the 
RUNX2 promoter region we could not detect any accumulation. This may 
suggests that RUNX2 may be regulated by ERβ binding to its promoter. 
However, on the adipogenic gene promoters, especially on FABP4 and Adipsin 
genes estrogen increases the accumulation of ERα receptor. We proposed that 
estrogen induction causes increase in the accumulation of ERα on PPARγ, 
C/EBPα, FABP4 and Adipsin genes recruiting corepressors/HDAC complexes 
to repress expression. In addition, the reason of the highest accumulation of 
ERα on FABP4 and Adipsin may be that these two genes are the downstream 
targets of adipogenic process.  
 
In order to investigate DNA methylation status of adipogenic genes upon 
estrogen administration, we focused on the master adipogenic genes; PPARγ, 
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C/EBPα and ERα promoters. Similar to a previous study59 in our experiment we 
have also observed mosaic CpG methylation profile on adipogenic gene 
promoters and variations in the percentage of CpG methylations between 
colonies (Figure 4.22). Our bisulfite sequencing analyses revealed DNA 
hypomethylation in C/EBPα and PPARγ promoters without estrogen (Figure 
4.21). On the contrary, estrogen treatment caused establishment of 
hypomethylation on the same genes in ovex cells. In both normal female and 
ovex colonies, DNA methylation pattern of ERα showed opposite profile. 
According to these results we concluded that epigenetic modifications do not 
regulate the adipogenesis process in the same way in MSCs isolated from 
female and ovex animals.  
 
In conclusion, in this thesis we have shown CNTs are ideal scaffold 
biomaterials to be used for seeding MSCs especially at P0 and estrogen 
enhances viability of cells on CNT arrays. Estrogen genetically and 
epigenetically regulates the expression of key transcription factors involved in 
MSC differentiation by not just changing the gene expression, protein 
localization of transcription factors involved in differentiation of MSCs, but 
also influencing binding of histone modification proteins and modifier enzymes 
to the promoter of these genes. Epigenetic mechanisms are reversible. That’s 
why, identification of genetic and epigenetic reprogramming of MSCs by 
estrogen treatment may provide an important insight for clinical applications in 
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both treatments of obesity, osteoarthiridis, osteosclerosis and tissue engineering 
applications.  
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CHAPTER 6 
FUTURE PERSPECTIVES 
 
In this thesis the effect of estrogen on maintenance and differentiation of MSCs 
was examined. We have found that estrogen treatment increases the 
maintenance of MSCs seeded on CNTs. Furthermore we have also shown that 
cell viability and the number of attached cells decreases through the passages. 
In order to  better understand whether estrogen treatment can enhance the cell 
viability on CNTs even if  in the later passages, detection of MSC viability on 
CNT arrays not only at P0, but also at later passages could be critical as to 
document the importance of positive effect of estrogen in tissue engineering 
field. Moreover, MSCs may undergo osteogenic or chondrogenic differentiation 
on CNTs arrays. The differentiation can be detected by using gold-label 
antibodies for osteogenic and chondrogenic markers and cell viability can be 
evaluated by MTT assay.   
 
In this study, we have mainly focused on the genetic and epigenetic alterations 
in regulation of adipogenic and osteogenic transcription factors. To explain the 
role of estrogen in the regulation of chondrogenesis, should be examined in a 
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dose dependent manner. To detect the optimum estrogen concentration, at 
which the expression of chondrogenic differentiation factors is stimulated, 
could be useful for further analysis.  Similar estrogen gradient pattern may be 
applied to invesitagate the transcriptional change of ETS1 gene.  
 
To investigate the total protein level of histone modifications and modifier 
enzymes, we unfortunately could use the protein samples isolated from one 
female and ovex animal. To confirm our results, the number of animal samples 
should be increase and the experiments should be repeated.  Similarly, to 
confirm the results and to calculate the fold change in the expression of the 
PPARγ, C/EBPα, FABP4, Adipsin and RUNX2 genes after the 
immunoprecipitation with histone modifications proteins, ChIP assay should be 
repeated using chromatin from MSCs obtained from more than one normal and 
ovariectomized female animal. ChIP experiment should be also performed for 
other histone modifications such as H3K9me2, H3K9me3 and H3K36me2 in 
MSCs. Also, knock-down of modifier enzymes such as LSD1, SET 7/9 and 
EZH2 using siRNA or shRNA both before and after differentiation, could 
provide the evalution of their contribution to control of differentitation.  
 
We also suggest that RUNX2 gene may have bivalent domain on promoter 
region and can be regulated by other active histone marks such as H3K4 and 
H3K36 in addition to H3K27. To test this possibility, ChIP should be 
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performed for H3K4, H3K36 and SET 7/9, which is a H3K4 methyltransferase. 
in MSCs. Accumulation of the active histone marks and SET 7/9 enzyme on 
RUNX2 gene can be quantified by qRT-PCR. 
 
Finally, in this thesis we suggest that estrogen induction causes increase in the 
accumulation of ERα on PPARγ, C/EBPα, FABP4 and Adipsin and ERα 
recruits EZH2 enzyme on these to repress expression. We do not know whether 
there is direct interaction between ERα and EZH2 protein or not. 
Understanding of how ERα represses the activation of adipogenic gene upon 
estrogen treatment is important while explaining the epigenetic effect of 
estrogen. Therefore,  the interaction of ERs not just with EZH2 protein, but also 
other HMTs, should be investigated by ChIP and co-immunoprecipitation 
analysis. 
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APPENDIX 
SOLUTIONS AND BUFFERS 
4% Paraformaldehyde (PFA)  
4 g PFA  
Complete volume to 100 ml with 1XPBS  
Dissolve by heating and constant stirring  
 
10% formaldehyde  
2 ml Formaldehyde  
18 ml ddH2O 
 
70% Ethanol  
70 ml 100% Ethanol  
30 ml ddH2O  
 
10x PBS (pH: 7,2)  
80 g NaCl  
2 g KCl  
8,01 g Na2HPO4.2H2O  
2 g KH2PO4  
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Complete volume to 1 Lt with ddH2O 
 
50X TAE Buffer  
 2M Tris Base (242 g)  
57,1 ml Glacial Acetic Acid  
50 mM EDTA  
Complete volume to 1 Lt with ddH2O 
 
1M Tris (pH:8)  
60.55 g Tris  
300 ml ddH2O  
21 ml 37% HCl  
pH adjusted to 8.0 with HCl, total volume brought to 500ml by adding ddH2O.  
 
 
Total Protein Lysis Buffer  
2 M NaCl  
1 M Tris pH:8.2  
0.9% Igepal CA-630 (Sigma, Germany, Germany) 
10x Protease Inhibitor Cocktail (Roche, Germany)  
778.5 μl ddH2O 
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Bradford Reagent  
100 mg Coomassie Brilliant Blue G-250  
100 ml 85% Phosphoric acid  
50 ml 95% EtOH  
Complete volume to 1 Lt with ddH2O 
Filtered through Whatman Paper  
 
10%SDS  
10 g SDS  
Complete volume to 1000 μl with ddH2O 
 
30% Acrylamide Mix  
145 g Acrylamide  
5 g Bis-acrylamide  
Complete volume to 500 ml with ddH2O 
Filtered, stored in dark at 40C.  
 
SDS-PAGE Running Buffer (5X stock solution)  
15 g Tris  
73,2 g Glycine  
5 g SDS 
Complete volume to 1L with ddH2O 
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Cracking Buffer (2X Protein Loading Buffer)  
50 mM Tris HCl pH: 6,8  
2m M EDTA pH: 6,8  
1% SDS  
20% Glycerol  
0,02% BFB  
Add 10% ß-mercaptoethanol prior to use  
 
10X TBS (pH:8)  
12.19 g Tris  
87,76 g NaCl  
pH adjusted to 8, Complete volume to 1Lt with ddH2O 
 
 
1X TBS-T 0.3%  
50 ml 10X TBS  
450 ml ddH2O 
1,5 ml Tween-20  
 
1X TBS-T 0.1% (pH: 7.5)  
50 ml 10X TBS  
148 
 
450 ml ddH2O 
500 μl Tween-20  
pH adjusted to 7.5 
 
Blocking Solution for Western Blot (5% BSA) (Histone protein)  
0.5 g BSA  
10 mL 1X TBS-T 0.1%  
 
Blocking Solution for Western Blot (4% milk powder)  
2 g Milk Powder  
50 mL 1X TBS-T 0.3%  
 
Semi-dry Transfer Buffer  
2,5 g Glycine  
5,8 g Tris base  
0,37 g SDS  
200 ml Methanol  
Complete volume to 1 Lt with ddH2O 
 
Wet transfer buffer for small proteins  
3 g Tris  
14.25 g Glycine  
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200 ml Methanol  
Complete volume to 1 Lt with ddH2O 
 
Coomassie Blue Staining Solution  
0,25 g Coomassie brilliant blue  
45 ml Mthanol  
10 ml Glacial acetic acid 
Complete volume to 100 ml with ddH2O 
 
Destaining Solution  
100 ml Methanol  
35 ml Acetic acid  
365 ml ddH2O 
 
 
Blocking Solution for Immunofluorescence (IF) Staining  
1 ml 2% BSA  
1 ml 1X PBS  
5 μl Tween-20  
 
2N HCl solution  
16.38 μl ddH2O 
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4.3 μl HCl  
 
TEB buffer  
0.5%  Triton-100  
0.02%  NaN3  
In 1XPBS  
Add 1X protease inhibitor prior to use   
 
LB  
10 g Tryptone  
10 g NaCl  
5 g Yeast extract  
Complete volume to 1 Lt with ddH2O and autoclave  
 
Agar  
10 g Tryptone  
10 g NaCl  
5 g Yeast extract  
15 g Bacto agar  
Complete volume to 1 Lt with ddH2O and autoclave  
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Adipogenic Induction Media (Prepared in DMEM –LG)  
1 μM Dexamethasone  
0.5 mM IBMX   
10 μg/mL Insulin  
100 μM Indomethacine  
10% FBS  
1% penicillin/streptomycin antibiotic solution  
 
 
 
Osteogenic Induction Media (Prepared in DMEM –LG)  
 
0.1 μM Dexamethasone  
0.2 mM Ascorbic acid ɣ-irradiated  
10 mM Glycerol phosphate disodium salt hydrate  
10% FBS  
1% Penicillin/streptomycin antibiotic solution 
 
